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Abstract 
Objective:  
This study prospectively investigated disease activity, functional disability and health-related 
quality of life (HRQoL ) in South Africans with early RA, and sought predictors of clinical 
response at 12 months to traditional disease modifying anti-rheumatic drugs (DMARD) 
treatment. In addition, the relationships between disease activity, circulating cytokines, the 
presence of auto-antibodies, the shared epitope (SE), and rheumatoid nodules (RN) were 
explored. 
Methods:  
A cohort of 171 patients with early (≤ 2 years) RA who were DMARD-naïve at inception were 
prospectively assessed for response to DMARDs over a 12-month period  using the simplified 
disease activity index (SDAI), the  Health Assessment Questionnaire-disability index (HAQ-DI) 
and the Short Form-36 (SF-36). At inception, rheumatoid factor (RF) and anti-cyclic 
citrullinated peptide antibodies (aCCP) were measured and genomic DNA was analysed using 
high-resolution PCR typing of the HLA-DR 1 allele. Circulating cytokines and growth factors 
were measured using the Bio-Plex® suspension array system.  
Results:  
 The 171 patients (140 females) at baseline had a mean age of 47 years, mean symptom 
duration of 12 months and had severe disease with a mean SDAI of 39, HAQ of 1.7, and 
globally low SF-36 scores. In the 134 patients seen at 12 months, despite significant 
improvements, only 28% achieved  low disease activity, and 69% still had substantial 
functional disability (HAQ-DI >0.5), and 66% had suboptimal mental health (SF-36 mental 
IX 
 
composite score <66.6). Baseline predictors of poor outcomes included unemployment, low 
level of schooling, female sex, high HAQ-DI and pain scores, and a low haemoglobin level. The 
6-months SDAI was better than the baseline SDAI in predicting the 12-month SDAI.  
The sensitivity and specificity of the aCCP test was 83%, and 85%, and the best specificity 
seen when both RF and aCCP were positive (95%). SE alleles were found in 92% of patients, 
and were strongly associated with aCCP, with disease activity and with proinflammatory 
cytokines. Circulating cytokines in RA reflect a multifaceted increase in immune reactivity 
with strong correlations between these cytokines, and auto-antibodies, in particular in the 
subgroup of patients with high disease activity. Subcutaneous RN were seen in 23% of 
patients, and were associated with more severe joint disease, and significantly higher levels 
of Th1 and macrophage derived cytokines, with significantly higher vascular endothelial 
growth factor levels. 
Conclusions:  
In this, the first prospective study of RA in sub-Saharan Africa, patients had severe RA, with a 
high disease burden at baseline and a high proportion carrying the SE allele, aCCP and 
rheumatoid nodules, with a multifaceted increase in circulating pro-inflammatory cytokines 
and growth factors. A large proportion of early RA patients have ongoing disease activity, 
substantial functional disability and suboptimal mental health despite 12 months of DMARD 
therapy. These findings, together with the high number of patients lost to follow-up, 
underscore the need for better disease control including an aggressive tight control strategy, 
and biologic therapy, and for patient- centred rehabilitation programmes with close links to 
psycho-social services.  
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Overview 
 
This thesis is a part of ongoing studies of the presentation and treatment of early 
Rheumatoid Arthritis (RA) patients in two public hospitals in South Africa: the Chris Hani 
Baragwanath Hospital, Soweto, and the Steve Biko Hospital. To argue for a patient-centred 
approach, an approach I hope will develop from this thesis; I begin with the story of Mrs 
Nomvula V, one of the patients who participated in the study. Her social and health 
conditions are typical of patients who present themselves for treatment in these state-run 
facilities.  
Chapter 1 provides an outline of the disease, introducing the focus on early diagnosis and 
therapy, as well as the rationale for and the results of a search for factors that might predict 
response to therapy. Socio-economic factors are examined in the context of the care and 
treatment of RA patients. The background to new diagnostic tests, genetic susceptibility 
markers, circulating cytokines and rheumatoid nodules in RA is discussed.  In order to better 
understand RA within the South African context, and to highlight the gaps in our knowledge, 
the findings of local studies done thus far are summarized, ending with the aim and research 
questions to be addressed in this thesis. 
Chapter 2 describes the methods used to answer the research questions. This thesis is based 
on patients enrolled in the GREAT (Gauteng Region Early Arthritis) registry, which is an 
observational longitudinal cohort of early RA patients. The study design is described, and 
details of the clinical assessments, radiographic and serological investigations performed are 
given. 
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Chapters 3 to 8 present peer reviewed manuscripts, each addressing the research questions 
outlined at the end of chapter 1. Each of these papers has a signed statement of originality, 
with a description of the contribution of each author to that paper in the appendices.  
Permission from each journal to include a copy of the published paper in this thesis has been 
obtained.  
Chapter 9 returns to Mrs Nomvula V, giving details of her disease at enrollment in the GREAT 
study in December 2007, and after 12 months of therapy in December 2008. Hereafter, a 
discussion of the results contained within each paper in the broader context of data derived 
from other studies and the field as a whole, using a framework of 4 themes to link the various 
aspects of the papers. The themes are:  
i. RA severity in Africans 
ii. Response to traditional DMARDs and routine clinic care 
iii. Being poor matters 
iv. Biomarkers of RA 
 Hereafter, a brief discussion of systems and strategies for the way forward, which 
summarize the implications at the level of clinical care; training of health care workers and 
future areas for research and planning. Limitations of the study are then discussed. 
Chapter 10 offers final conclusions, followed by a reference section and appendices. 
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“Life is more than just living, more than the number of days lived… it is the meaning of 
things, of relationships, and the quality of life and where it is lived that are important” 
David Blumsohn “The Pathology of Poverty” 1989 1
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Mrs Nomvula V’s story 
Mrs Nomvula V was born in 1953 in Soweto, South Africa, and is one of 7 children. She completed Grade 8 but 
left to take care of her grandmother in Idutywa, near Butterworth in the Eastern Cape. Her first child, a boy 
named Luthando, was born there when she was 20 years old (1973) and Neliswa, a girl, was born in 1975. Mrs 
Nomvula V returned to Soweto after her grandmother’s death in 1977 with Luthando, now 4 and Neliswa aged 2. 
In 1982 a girl, Thobeka, was born.  
Mrs Nomvula V now lives in a 1-room outbuilding in Diepkloof, Soweto, and is separated from the father of her 
lastborn child. The room has electricity, but no bathroom or indoor toilet. She is the caregiver of three children 
who share the single room. Her youngest daughter Thobeka died of AIDs in 2005, leaving her two children (now 
aged 4 and 7). Her sister suffered a stroke and died in 2004, and Mrs Nomvula V has taken in her sister’s 
grandchild, Pretty, aged 11, as the child’s mother abuses alcohol. Mrs Nomvula V has never been formally 
employed, but had an income from selling fruit and cigarettes at a street-side stall near her home in Diepkloof. 
Until the onset of the disease, she was an active person, never one to sit around. Her days began early, heating 
water to wash, and getting the two older children dressed and ready for school, and then setting off with the 
youngest child to her stall where the day was filled with socializing with passers-by, customers and neighbours. 
She made weekly trips into town to buy supplies, leaving the child with neighbours for the day. Sundays were 
church days, and upon returning home she cleaned the room and washed the family’s clothes for the week ahead. 
In early 2006, Mrs Nomvula V’s fingers and knees became painful and swollen. She visited her local clinic where 
she was given pain tablets. These did not help her much, and she struggled to manage, particularly in the morning 
when her hands, knees and ankles “would not get going”. Increasingly she struggled to complete tasks, such as 
dressing herself and the young children and cooking meals for the household. Washing and ironing became 
impossible. By late 2006 she was relying on Pretty to help with most of these household chores before and after 
school. Some mornings she could not walk to her vending station because her knees were so painful. It became 
more difficult to travel to town to restock her supplies by public transport. She struggled most with getting on and 
off a minibus taxi after her joints had stiffened up, and carrying the produce because her hands and shoulders 
were painful and weak. Eventually she stopped selling goods and relied on Luthando, who worked as an 
electrician, for financial support. 
 She said “I thought life was hard before this arthritis came, but now I really understand…”.  Feelings of 
hopelessness began to overwhelm her. She spent more and more of her time lying on her bed in her room, 
overwhelmed by pain and exhaustion. She stopped attending church and social occasions.  
At the clinic, she waited in long queues and was usually given pain tablets and Indomethacin. One of the doctors 
she saw told her she had gout and old age and should stop drinking alcohol and eating tomatoes, neither of which 
she did. In late 2007 she met a new doctor at the clinic and asked him if he could help her apply for a disability 
grant. He performed some blood tests, and referred her to Chris Hani Baragwanath Hospital to complete her 
application forms. Mrs Nomvula V was seen in casualty, and referred to the Arthritis Clinic. She was assessed as 
having Rheumatoid Arthritis and enrolled in the Gauteng Region Early Arthritis (GREAT) study.  
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Chapter 1: Articulating RA: the beginnings of the GREAT study 
 
1.1 Background 
 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease occurring 
worldwide, characterized by inflammation of both small and large synovial joints. This 
inflammation results in bony erosions and eventually destruction of the joint. The disease 
affects almost 1% of the adult population  and carries substantial socio-economic impact to 
affected individuals and their societies2. Studies conducted in Western populations show that 
Rheumatoid Arthritis is one of the leading causes of physical disability, with more than half of 
patients deteriorating to severe functional disability after 10 years of disease3. In addition, 
the burden of pain and reduced health-related quality of life is considerable4, and RA patients 
have a two-fold higher risk of depression compared to the healthy population5,6. Life 
expectancy is reduced by 3 to 7 years, with the leading cause of death being infection and 
cardiovascular disease7. Survival rates for RA are similar to those for lymphoma, diabetes 
mellitus, stroke or coronary artery disease8 . The disease carries substantial economic impact 
due to both direct costs including medical care, treatment and hospitalization, and indirect 
costs as a result of productivity loss, with its consequences on the individual, the employer 
and society9. Only 50% of patients are still employed after 15 years of disease3.  
There is a variable course of the disease with remissions and exacerbations, and the outcome 
is diverse, ranging from mild intermittent non-destructive disease to rapidly progressive 
disabling arthritis. 
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1.1.1 Why early RA? 
 
There has been a recent shift in treatment strategies for RA. The first therapeutic approach 
included bed rest and anti-inflammatory drugs, and disease modifying anti-rheumatic drugs 
(DMARDS) were reserved for patients with established deformities and ongoing severe 
disease. In the mid-1980s it was recognized that such an approach was suboptimal, with 
most patients showing progressive radiological damage10, long term functional decline, work 
disability11, and premature mortality12.  
This led to a revolutionary approach to management of RA, with early and aggressive use of 
DMARDs to suppress inflammation and achieve a low disease activity state before 
irreversible joint damage had occurred13,14. Initiating early treatment allows better control of 
disease, with a higher possibility of achieving remission which may be maintained even once 
DMARD treatment is withdrawn15. It is postulated that the biological process in early RA 
differs to that in established disease, and therapy to rapidly suppress inflammation in its 
early stages may change the pathway of the disease for years to come16. Hence treatment 
started during this early “window of opportunity” has a greater effect than treatment given 
at a later stage17. 
Numerous studies have confirmed the benefits of early DMARD therapy, including the 
prevention of radiographic damage and preservation of functional ability18,19. Underscoring 
this, a meta-analysis showed disease duration to be the primary predictor of response to 
treatment20. The benefits of early DMARDs are still apparent after 10 years of follow-up21 
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where functional status is maintained in patients treated within 6 months of symptom onset 
as compared to those who started treatment later. 
1.1.2  What is early RA? 
 
With the drive to treat RA as early as possible, comes a need to diagnose RA promptly and 
accurately, but both the terms “early” and “RA” have an indeterminate aspect. The symptom 
duration defining the disease as ‘early’ differs widely in the literature. Symptom duration of 
less than 24 months is regarded as a reasonable definition of ‘early’ disease, although 
recently a symptom duration less than 6 months has been considered early disease22, and 
“very early disease” defined as symptom duration less than 12 weeks23.  
Early diagnosis of RA is challenging, because in its initial phases RA may be difficult to 
distinguish from other types of inflammatory rheumatic conditions, some of which are self-
limiting. The diagnosis is clinical, with serological markers lending support. The American 
College of Rheumatology (ACR) has developed classification criteria24 to distinguish 
established RA from other rheumatological conditions in the research setting. These criteria 
have only a moderate sensitivity and specificity in early inflammatory arthritis25.  Hence, the 
ACR criteria have very recently been revised, to address this poor performance in early 
disease26. 
1.1.3  Response to traditional DMARDs 
 
Traditional DMARDs include methotrexate (MTX), chloroquine (CQ), sulphasalazine(SSZ) as 
monotherapy or in combination, and these may be combined with low dose corticosteroids. 
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In recent years, biologic DMARD drugs have been developed for the treatment of RA and 
other inflammatory conditions. These agents target specific molecules involved in the 
pathogenesis of RA, and have the potential to induce a rapid and sustained suppression of 
disease. In early disease, they achieve remission in 40-50 % of patients, thus preserving 
functional ability and preventing joint destruction27-29. Despite their effectiveness, the use of 
biologics is very limited in developing countries due to the risk of serious infection including 
tuberculosis associated with their use, and by their high cost. A major challenge is to 
implement these growing treatment options into everyday clinical practice.   
Baseline predictors of response to DMARD therapy could assist in tailoring individualised 
treatment.  A patient with a good prognosis is likely to respond to methotrexate 
monotherapy, whereas a patient at high risk of rapidly progressive disease should perhaps be 
started on combination traditional DMARD or biologic DMARD therapy at diagnosis. Such an 
approach may allow optimum benefit in a resource-constrained setting. 
  Predictive factors may be categorized as demographic factors, disease specific 
features and genetic or biologic markers. Key studies, and meta-analyses in particular, which 
have offered prognostic factors for either response to DMARDs or functional disability in 
early RA are summarized in Table 1.1. Demographic factors conferring a poor prognosis 
include female sex, older age at disease onset, cigarette smoking, and having a poor 
socioeconomic background. Disease-specific poor prognostic factors identified thus far are 
long symptom duration, high disease activity at baseline including high swollen and tender 
joint counts and elevated inflammatory markers, high composite disease activity scores and 
low haemoglobin level. High functional disability at onset bodes a poor prognosis. The 
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presence of auto-antibodies is associated with worse radiological damage and a higher 
occurrence of extra-articular disease. Extra-articular disease itself is a marker of poor 
prognosis. Genetic factors play a role in the severity of RA, and most studies demonstrate 
that the presence of the HLA-DRB1 shared epitope is a poor prognostic marker30. Biological 
markers including levels of certain synovial and serum cytokines show promise as predictors, 
but further work in this field is necessary before recommending their use in routine clinical 
use31. 
1.1.4  The impact of socio-economic status 
 
The association between socio-economic status (SES) and mortality and morbidity has been 
described for centuries, with poor living conditions impacting negatively on health and on 
response to treatment. This socio-economic gradient persists into the 21st century despite 
advances in the understanding of diseases, their pathogenesis and diagnosis, and 
tremendous improvements in treatments available. Worldwide, poorer communities are 
more often and more severely affected by acute and chronic, communicable and non-
communicable diseases32,33.
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Table 1.1: Predictors of response to DMARD therapy and functional disability in early RA - summary of key studies  
 
 
 
 
 
 
 
 
 
 
 
 Marker of Poor Prognosis Response to therapy Functional Outcome 
Demographic  Factors Older age at onset 34,35 36 
Female Gender 20,37 36 
Smoking 37,38  
Socio-economic factors See Table1.2 
Disease Specific 
Factors 
Delay in DMARD therapy 20,21,39 40 
High Baseline functional 
disability 
20,37,41 42-45 
High Baseline Pain 46 47,48 
High Baseline Disease 
activity 
37,49 42,45 
Rheumatoid factor 49 42 
Anti CCP  46,50  
Radiographic Erosions 43 42,45 
Depression 46 51 
Extra-articular disease 52  
Genetic / Biologic 
Factors 
HLA-DRB1 Shared Epitope 30,53  
Methotrexate pathway 
genes 
49,54  
Circulating TNF-a 55  
Circulating  IL-2 56  
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Table 1.2: Impact of socio-economic status on rheumatoid arthritis disease expression 
↑:  increased, ∆:  change
Author, Year 
 
Country Measure of SES Disease 
Activity  
Functional 
Disability 
Pain Mental 
Health 
Damage    Other findings  
Pincus T 
198732 
USA Formal education level ↑ ↑ ↑ --- --- Most chronic diseases 
including RA more 
prevalent 
McEntegart 
A 199757 
UK Carstairs index of 
social deprivation 
No ∆ ↑ No ∆ --- --- ↑ mortality 
Callahan LF 
198858 
Nashville 
USA 
Formal education level ↑ ↑ ↑ --- ---  
Brekke M 
199959 
Norway Affluent vs less 
affluent suburbs of 
Oslo 
No ∆ ↑ --- ↑ No ∆  
Jacobi CE 
200360 
Netherlands Formal education level ↑ ↑ --- ↑ ---  
Harrison MJ 
200561 
UK Townsend score of 
social deprivation 
↑ ↑ ↑ ↑ No ∆  
Solomon A 
200562 
SA Public care vs private 
care  
↑ ↑ ↑ --- ↑ deformity 
score 
 
Pincus T 
200763 
USA Formal education 
levels 
--- ↑ --- --- --- ↑ mortality 
Sokka T 
200964 
25 countries High GDP vs low GDP 
countries  
↑ ↑ ↑ ↑ ↑ Fewer on biologics 
Neovius M 
201165 
Sweden Formal education level --- --- --- --- --- Higher prevalence of 
RA 
Margaretten 
M 201166 
USA Public hospital vs 
university tertiary care 
↑ ↑  ↑↑ ---  
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Amongst RA patients, studies from various countries give strong evidence that a poor socio- 
economic background predisposes patients to poorer outcomes across all measures. Table 
1.2 summarizes studies that demonstrate the negative impact of poor SES on disease activity, 
functional disability, pain, mental health, radiological damage and mortality. Interestingly, a 
Swedish study recently reported that the prevalence of RA is influenced by level of 
education65. As Brekke et al conclude, affluence seems to buffer against the burden of RA59.  
There are various ways to measure SES. Some studies have used a social deprivation index 
based on area of residence57,61. Others used the health care institution patients attend as a 
marker for indigence or affluence62,66. Level of formal education has been used by many as a 
surrogate marker for SES, and is a good marker because of its simplicity, reliability, and the 
fact that it is uninfluenced by an adult-onset disease32,60.  
1.1.5  Tools to measure RA: disease activity, functional disability and HRQoL 
 
Disease activity can be assessed with a composite score derived from the tender and swollen 
joint counts, the global assessment of patient and physician, and an acute phase response 
(either CRP or ESR). Two such scores are the 28 joint disease activity score (DAS-28), and the 
simplified disease activity index (SDAI)67,68. Both scores are validated and show good 
intercorrelation, with the SDAI having the advantage of being easy to compute in the clinical 
setting. The SDAI can be regarded as validated in the South African population, because 
South African patients were included in the database used to show construct and content 
validity69. 
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 There are many ways of assessing response to therapy in RA. Traditionally clinical trials and 
studies have reported relative change in disease activity from baseline, expressed as 
response criteria like the ACR 20/50/70. In order to fulfill the criteria for an ACR20 response, 
a patient must have improved by 20% (or 50% or 70% in the case of ACR50 and ACR70 
respectively) with respect to tender and swollen joint counts, and in three of the remaining 
five criteria (pain score, acute phase reactant, physician and patient global assessments and 
physical disability score)70. Recent work shows the importance of absolute disease activity 
state at endpoint, such as the SDAI, because this state is more strongly associated with 
functional disability and radiological damage than level of response from baseline71. Besides, 
as Moons et al commented “Prognostic studies should focus on outcomes that are relevant 
to patients” 72. In RA, these might include pain and disease activity, physical function, and 
quality of life at the end-point, rather than the percentage improvement from baseline. For 
these reasons, this study used absolute disease activity states at 12 months to assess 
response to therapy. 
 
Disease activity indices alone fail to assess the extensive multi-dimensional issues associated 
with a chronic illness. The goal of modern RA therapy encompasses such broad objectives as 
restoration of an individual’s functions of daily life and psychological health, and preservation 
of social and occupational roles. Accordingly, emphasis is now placed on health-related 
quality of life (HRQoL) assessments in RA. Such measures of HRQoL in RA reflect the 
inflammatory process in the joints and show good correlation with clinical disease activity73, 
and are responsive to treatment74. Poor HRQoL scores are predictive of long term disability 
11 
 
and mortality63. Measures of HRQoL are a good indicator of the indirect costs of RA75. One 
further and important reason to evaluate HRQoL in RA is that these tools incorporate the 
patient’s perspective and thus give important information about an individual’s health status 
that would otherwise be overlooked76. 
The Health Assessment Questionnaire – Disability Index (HAQ-DI) and the Medical Outcomes 
Short Form-36 (SF-36) are complementary self administered questionnaires that have been 
validated to measure HRQoL77,78. The HAQ-DI was specifically developed for RA and consists 
of 24 questions that evaluate physical function in eight domains, and the composite score 
ranges from 0 (no disability) to 3 (severe disability). The SF-36 is a general measure of overall 
health and psychological well-being that examines eight domains, four of which constitute 
the physical component score (pcs). These are physical functioning (ability to perform various 
activities), role-physical (problems with daily activities due to physical health), body pain and 
general health. The other four make up the mental component score (mcs) - mental health 
(anxiety or depression), role-mental (problems with daily activities due to emotional state), 
vitality and social functioning. Scores in each domain range from 0 to 100, with higher scores 
reflecting better health. Construct and content validity of the English version of the HAQ-DI 
and SF-36 questionnaires has been shown in this population in a study of HRQoL in RA and 
SLE patients79. 
1.2  New diagnostic markers: Anti-cyclic citrullinated peptide antibodies 
 
Rheumatoid Factor (RF) is the principal serological marker for RA, and is present in up to 80 % 
of established RA patients, but is only present in about 50% of  patients with early disease80. 
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Furthermore, the RF test has limited specificity (85%) because it is detected in other 
connective tissue diseases, chronic inflammatory and infectious diseases, as well as in the 
healthy elderly population80,81. Recently anti-cyclic citrullinated peptide antibodies (aCCP) 
have emerged as sensitive and specific serological markers of RA. Citrullination is a post-
translational modification of arginine by deimination, physiologically occurring during 
apoptosis, inflammation or keratinization. The presence of several citrullinated proteins has 
been demonstrated in inflamed synovium82. 
 These antibodies have a low to moderate sensitivity for RA (50-70%), similar to RF, but may 
pre-date the onset of RA83,84. Importantly, they are highly specific for RA (over 96%), and are 
thus particularly useful in diagnosing early RA85,86. Moreover, aCCP antibodies offer 
prognostic information, predicting future radiographic damage82. 
1.3  Genetic susceptibility: the shared epitope 
 
Genetic predisposition may contribute up to 60% of the risk of developing RA87.  The major 
susceptibility for RA lies in the HLA-DR genes whose β1 chain contain the shared epitope (SE) 
conserved amino acid sequence88. Alleles expressing this SE are associated with susceptibility 
to RA, accounting for approximately one-third of the genetic susceptibility to the disease89. In 
addition, most studies show that the SE confers more severe disease with a greater risk of 
radiographic damage90,91. The HLA-DRB1 concept has recently been extended to include the 
SE sequence at positions 72 to74 together with modulatory amino acids at positions 70 to 72, 
and reclassified into five allele groups92. This classification has allowed “risk stratification” of 
13 
 
genotypes, with alleles S2 and S3P carrying the highest risk of developing RA, whilst S1 alleles 
appear to be protective93,94.  
There are several models to explain the role of HLA-DRB1 genes in the loss of self-tolerance 
that results in autoimmune disease. The HLA molecule binds specific peptides and presents 
them to CD4+ T lymphocytes via recognition by the T cell receptor. Molecules containing the 
SE bind a different array of peptides than those not containing it95. Recently, it has been 
shown that the SE confers susceptibility to RA mainy in aCCP positive individuals96,97. Hence, 
the immunopathogenesis of aCCP-positive RA may involve presentation of citrullinated 
proteins by HLA-DRB1SE subtypes, resulting in activation of autoreactive T cells98. In addition, 
the high affinity of citrullinated peptides for the epitope may “skew” the response towards a 
Th1 direction99.  
1.4 Circulating Cytokines 
 
Several components of the immune system contribute to rheumatoid inflammation, 
including T lymphocytes, macrophages, fibroblasts, B lymphocytes, and endothelial cells. 
Maturation and proliferation of these cells results in synovial inflammation together with 
cartilage and bone damage, and systemic manifestations of RA. Cytokines, chemokines and 
growth factors, operating in complex cascades and networks, orchestrate this immune 
response in RA100,101.  
Recent studies have shown elevated levels of circulating pro-inflammatory cytokines in RA 
patients102,103. Such assays may broaden our understanding of the immunopathogenesis of 
early and established RA, revealing novel therapeutic targets. In addition, profiling of 
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circulating cytokines may allow response to therapy to be predicted. Recently, Fabre et al 
showed that high serum levels of MCP-1 and epidermal growth factor (EGF) at baseline were 
predictive of a good clinical response to an anti-TNF drug, etanercept at 3 months104. Serum 
TNF and IL-2 levels may predict response to DMARD therapy55,56. 
1.5  Rheumatoid nodules 
 
Rheumatoid nodules (RN) are the most common extra-articular feature of RA, occurring in 
approximately 20-30% of patients 105.  These subcutaneous nodules occur on extensor 
surfaces at sites of mechanical irritation. Although benign, RN are of clinical significance to 
the patient and clinician because they may be painful when exposed to repeated minor 
trauma, they may be sites for infection, and may be unsightly. Importantly, the presence of 
nodules are a marker of disease severity, particularly if seen early in the disease, and may 
herald the development of other extra-articular disease52,106. Nodules are a risk factor for 
premature mortality in RA patients107,108.   
The prevalence of RN differs between ethnic groups, with the highest prevalence described 
in Caucasians in Europe and North America, and a lower prevalence in Mediterranean 
countries109. In the few studies of RA in Africa a low incidence of RN has been noted in 
Nigeria (1%)110, Cameroon (7%)111, and Uganda (8%)111. Studies in black South Africans and 
Kenyans report a prevalence close to that of patients of European  ancestry112-114. The reason 
for this spectrum of prevalence is unclear, but may be linked to genetic or environmental 
factors such as smoking115. 
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The association between genetic susceptibility, specifically the SE and RN is controversial. 
Two large meta-analyses and other small studies show no significant association between SE 
and nodulosis 116-118. Other reports have shown an association between the SE and RN 119,120, 
and in particular the SE-containing alleles DRB1*0401121. The low frequency of HLA 
DRB1*0401 in African-Americans122,123 and Africans from Cameroon111 and Senegal124 has 
been suggested as an explanation of the low incidence of RN in these populations. 
 Histopathologically, the RN is an immune granuloma consisting of a central area of necrosis, 
surrounded by a “palisade” of macrophages and fibroblasts, and a peripheral vascular area 
containing T lymphocytes and macrophages 125. A number of studies have drawn 
comparisons between the RN and rheumatoid synovium, describing similarities between the 
tissues with respect to cellular components, immunohistochemical features and cytokine 
production 126-129, but important differences have been shown with regards to B lymphocyte 
and fibroblast populations and cell adhesion molecules and cytokine expression 130-132. In 
addition to immunohistochemical differences, nodules and synovitis do not run the same 
clinical course: patients with low disease activity can still develop RN, and increase in nodule 
size or formation of new nodules is well described with therapy that effectively suppresses 
joint inflammation, such as methotrexate and anti-TNF drugs 133-135. This again suggests that 
the pathogenetic mechanisms of joint inflammation and RN differ.  
1.6.1  RA in the developing world 
 
There is increasing awareness of the global burden of all non-communicable diseases, and 
developing countries carry the brunt of the mortality and morbidity from these conditions136. 
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However, much of the work on epidemiology, pathogenesis, disease characteristics and 
therapy of RA has been conducted in developed countries, with relatively little information 
on the disease in the developing world which includes South America, South-East Asia and 
Africa137. The few formal epidemiological studies conducted in developing countries, most 
show a lower prevalence of definite RA than in northern European and American 
populations138,139. This may be due to a true lower occurrence in these regions, or may reflect 
underestimation of the disease due to methodological variations in these studies140.  An 
Indonesian study suggested reduced life expectancy together with a high mortality from RA 
may explain the low prevalence in this population141, and this may be true of other 
developing countries. A recent review of RA in India and Pakistan shows a prevalence of RA in 
these countries similar to that in Europe and North America, but demonstrates that 
differences in clinical features do exist142. 
Several studies have compared clinical features of RA in different areas of the world110,143-147. 
The general impression is that disease is more severe amongst Europeans. Despite the 
difficulty in comparing populations directly, with potential sampling errors together with 
poor age and disease duration matching of cohorts, these studies highlight not just the 
diversity of RA expression, but also the importance of cultural and socio-economic influences 
on disease and its consequences. Conclusions reached about, for example, functional 
disability and its associations in one part of the world may not be true in another. 
Hence research into RA in developing countries is urgently needed to provide better 
information about prevalence, clinical features, and response to therapy together with the 
underlying genetic, cultural or socio-economic determinants of outcomes. In resource-
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constrained settings, appropriate planning, monitoring and implementing of health care 
services depends on information from such studies. 
“It is not because countries are poor that they cannot afford good health information.  
It is because they are poor that they cannot afford to be without it.” 
WHO Health Metrics Network ; 2005 
1.6.2   Sub-Saharan Africa and South Africa 
 
There is no evidence that RA existed in Africa before the 20th century, but the prevalence is 
now increasing 148. Whether this is a result of an infective agent, a susceptibility gene 
introduced to the African gene-pool, decreasing incidence of protective infections or the 
result of an increasingly urban lifestyle remains uncertain. Some of the lowest prevalence 
rates of RA in the world (0.1-0.28%) have been described in Southern Africa149-151. This has 
been attributed to climate and possibly altitude, where tropical infections including malaria 
may be protective against autoimmune disease. In addition, a “rural-urban” gradient has 
been suggested to account for the discrepancies in prevalence between regions, and a more 
than 3-fold increased prevalence amongst city dwellers suggests that an environmental 
factor precipitates RA152. This phenomenon has also been observed in Nigeria153.  
Another explanation offered for the low prevalence of RA in Africa is the lower prevalence of 
susceptibility genes. In the relatively few studies assessing HLA-DR genes in Africa, it has been 
shown that although SE-containing alleles are associated with susceptibility to RA, the 
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frequency of the SE is lower in the background population and in RA patients compared to 
European populations. Table 1.3 shows key studies in various populations, highlighting work  
done in Africa. The allele profile in populations of African origin is distinct from that of 
Caucasian populations, with a low frequency of certain alleles including HLA DRB1*0401 (S2 
in the new classification) described in African-Americans153. The low incidence of RA, mild 
disease and paucity of extra-articular disease has been attributed to these differences. In the 
southern African RA population, the frequency of the SE is higher than that reported 
elsewhere in Africa. Amongst the San population, 52.2% carry the risk alleles93. 
With the impression that the prevalence of RA is increasing, , it becomes clear that there is a 
need for large epidemiological surveys in sub-Saharan Africa159. 
Rheumatoid arthritis has long been regarded not only as rare, but also as a mild disease on 
the African continent. Here again there are relatively few studies, and methodological 
discrepancies between many of these studies make direct comparisons difficult.  In addition, 
most studies have been performed in hospitals, and may not be a reflection of the overall 
disease in the general population, where the very ill and disabled are unable to attend, or 
milder cases are not seen. A further consideration is that the demographic features of the 
background population structure may influence the age and gender of RA patients described 
-for example, men may be in the cities at work under a migrant labour system, explaining the 
skewed gender ratios.  
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Table 1.3: Frequency of HLA DR β1 alleles in key studies in Europe, African Americans and 
Africa 
 
 
 
  
Investigator 
and year 
Population RA 
patients 
% with 
HLA DRβ1 
Controls % 
with HLA 
DRβ1 
Relative 
risk 
Comments 
Thomson W 
1998154 
United 
Kingdom 
59 44 5-fold HLA–DRB1p0404 (ie S3p) strongest 
susceptibility 
Hughes 
2008123 
African-
Americans 
25.2 13.6  Higher level of European 
admixture associated with a higher 
likelihood of carrying the SE  
Dieye A 
1996124 
Senegal 25.2 13.6 30 for 
DR10 
HLA-DR10  
 but not HLA-DR4 
Singwe-
Ngandeu 
2010111 
Cameroon 30 10   
Barnetche 
200793 
San 52.2 26 3.05 S2 allele 
26 21 1.32 S3p allele 
Mody 
1989155 
South Africa 44 10 7.4  
Martell 
1989156 
South Africa 
(Black 
patients) 
38 13 3.9  
Meyer P157 South Africa 
(Black 
patients) 
46 12 6.1 Particularly HLA-DRB1*0401 and 
*0404 alleles 
Pile 1992158 South Africa 
(Black 
patients) 
78 24   
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Table 1.4 summarizes studies of RA in sub-Saharan Africa.  Younger age at disease onset 
together with a higher female preponderance than described in Europe is reported110. Milder 
disease, fewer extra-articular complications and little negative impact on functional ability 
have been described160,161 , but recent studies show that severe disease is more common 
than previously assumed. Mody et al showed 56% of RA patients in the Western Cape have 
severe disability112. Late presentation (a mean 2.7 years delay in referral for treatment) and 
disability at presentation were the chief determinants of  functional disability in Sowetan RA 
patients in a retrospective study, and after a median follow up period of 3.3 years, a third of 
patients had severe disability113. A cross-sectional study with established RA have shown 
poor HRQoL and impaired functional ability79. Solomon et al demonstrated high disease 
activity and substantial functional disability, particularly amongst public care patients. A high 
prevalence of depression amongst urban RA patients was recently reported162. Schneider et 
al highlight the additional burden of poverty carried by women with RA in Soweto, where low 
income and the lack of services compound pain, social exclusion and loss of independence 
163. The lack of social support and poor infrastructure of health care services are important 
considerations in developing countries and mean that a chronic disabling illness has a greater 
impact on patients and their dependants than in an industrialised country. Poor public 
transport facilities and lack of electricity, outdoor toilets and lack of hot water geysers are a 
reality for many of these women. Such services and facilities could mitigate the symptoms as 
well as the lack of independence associated with RA. 
The majority of participants in the GREAT study are resident in Soweto, South Africa and its 
surrounds. Soweto's origins go back to early 1900’s when black Africans were accommodated 
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on the outskirts of Johannesburg under the apartheid regime. The economic development of 
Soweto was severely curtailed by the apartheid state, which provided very limited 
infrastructure. Today, Soweto is home to about 1.5 million people, and despite some 
development, many areas remain impoverished, with an estimated 53% unemployment 
rate167. Most homes are "matchbox" houses, or four-room houses built by the government 
(Figure 1.2). Informal squatter camps have developed in the poorer districts with almost no 
infrastructure, with many residents sharing one tap and a portable toilet.  Soweto was meant 
to exist only as a dormitory town for labourers who worked in white homes, factories, and 
industries and even today almost all of its residents are public transport commuters to other 
parts of the city. Moreover, in the last two decades, the population of Soweto has been 
devastated by the HIV/AIDs epidemic, with older women becoming centrally involved in 
raising grandchildren orphaned by the disease. There are only 50 registered rheumatologists 
in South Africa, giving a ratio of 1 rheumatologist per million (0.025/25 000) people as 
compared to developed countries, for example France, where the ratio is 1/25 000. These 
factors, together with health budget constraints, mean limited therapeutic options are 
available, and speak to the urgent need for careful planning of future health care services at 
all levels. This requires research into musculoskeletal diseases, as models used in developed 
countries may not apply in sub-Saharan Africa.  
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Table 1.4: Severity of RA in sub-Saharan Africa- a summary of key studies and their major findings 
RF: Rheumatoid factor; F:M: female to male ration; C: cross sectional; R: retrospective
Year Study 
design 
City, 
country 
No 
of 
pt 
Disease 
duration 
(yrs) 
Positive 
RF (% ) 
F:M 
ratio 
Age 
of 
onset 
(yrs) 
Radiographic 
erosions (%) 
% with 
nodules  
Disability 
(Functional 
Class 3 or 4) 
Treated 
with 
DMARD 
(%) 
Comments 
1988-
2002160 
R Kinshasa 
DRC 
82 6 63 3.5:1 45.3 No erosions 0.01 
(1/82) 
_ _ Uncommon, 
mild 
1989112 C Cape 
Town, SA 
52 8.2 87 3.7:1 44.6 +++   25 29/52 65 Severe disease 
1991110 C Ibadan 
Nigeria 
23 2.7 48 1.5:1 33 30 8.4 5/23  Young age of 
onset 
1994145 C Harare, 
Zimbabwe 
84 5.8 77.8 3.9:1 49 +   25 mean HAQ 
2.8 
89 No urban/rural 
differences 
1998161 R Congo-
Brazzaville 
36 9.5 70 28:0 43.5 100 0.04 
(1/28) 
0.3 
(8/28) 
_ Nodules rare  
2003113 R Soweto, 
SA 
182 7 87 6.9:1 40.7 _ 19 49 93 Late 
presentation, 
severe disease 
2003164 R Lagos, 
Nigeria 
200 5.3 38.5 2.4:1 46.9 29.2 30 _ 100 Common, 
severe 
200579 C Soweto, 
SA 
100 9 90 _ 40.5 ++  _ mean HAQ 
1.2 
_ Impaired 
HRQoL 
2009165 C Kenyatta 
Kenya 
60 9.5 79 6.5:1 41.4 _ 13 _ 47 Active disease 
2009166 C Dakar, 
Senegal 
100 4.5 78 7.3:1 40.3 56 0.03 _ _ Delayed 
diagnosis, 
severe disease 
2010111 C Yaoundé, 
Cameroon 
56 3 43 19:1 53.5 44 7 _ 91 Active disease 
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1.7  The gaps in our knowledge 
 
South Africa has a unique combination of excellent clinicians and up to date scientific 
laboratory services, with a large indigent population dependent on state hospital services. In 
this resource constrained setting, information on early RA, its severity and response to 
available inexpensive therapy, together with the factors which influence outcome in terms of 
disease activity, functional disability and HRQoL are vital for planning of future health 
services at all levels. In addition, newly diagnosed South African patients need information on 
how the disease is likely to affect major aspects of their lives.  
Figure 1: a photograph of Soweto, South Africa taken from Chris Hani Baragwanath Hospital, where the 
majority of women and men in this study live. 
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To date, there are no published prospective longitudinal studies on response to therapy in 
early RA patients in sub-Saharan Africa, and few in the developing world. Similarly, there are 
very few studies focusing on functional disability and HRQoL emerging from the developing 
world.  Most studies of aCCP antibodies have been carried out in patients of European 
ancestry, and the clinical utility of aCCP antibodies in diagnosing RA has not yet been defined 
in a sub-Saharan African population. Better understanding of the circulating cytokines in 
serum of patients with early disease might offer clues to the immunopathogenesis of RA, 
may provide novel biomarkers for assessing therapy, and may offer novel targets for future 
biologic therapy. There are currently no studies centred on rheumatoid nodules and their 
associations in Southern Africa, and little work exploring the cytokine profile of such patients.  
1.8  Objective and Research Questions 
 
We set out to study early RA in modern urbanized predominantly black South Africans, and 
to explore the various facets of the disease. The investigation centres on the individual 
patient with RA, and each of 6 research question focuses on the disease and its 
consequences at levels which may include genetic, immunological, physical, functional and 
psycho-social facet of an individual’s life.  
Research question 1: (addressed in Chapter 3) 
What are the baseline clinical characteristics of early RA in this population, and which 
demographic, clinical and laboratory features predict response to therapy?  
 
 
25 
 
Research question 2: (addressed in Chapter 4) 
What is the burden in terms of functional ability and quality of life, with particular emphasis 
on mental health, at baseline and after 12 months of treatment? 
Research question 3: (addressed in Chapter 5) 
What is the clinical utility of the aCCP test in this population? 
Research question 4: (addressed in Chapter 6)  
Are various shared epitope subtypes associated with autoantibodies, and with clinical and 
circulating biomarkers of disease activity? 
Research questions 5: (addressed in Chapter 7) 
What are the circulating cytokine profiles of early RA patients?  
Do circulating cytokine profiles correlate with acute phase reactants, autoantibodies, and 
disease activity? 
Research question 6: (addressed in Chapter 8) 
What is the occurrence of rheumatoid nodules in this population of early RA patients, and are 
they associated with disease activity, radiographic damage, autoantibody status, the 
presence of the shared epitope, and circulating cytokines?  
The findings will be discussed according to 4 major themes. Key points from each chapter as 
applicable to each theme are shown in Table 1.5. This matrix serves as the framework that 
will structure the discussion in Chapter 9.  
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 Table 1.5 Key points from each chapter applicable to major themes of the thesis 
 Background 
 
(Chapter 1) 
 
Predictors of 
response 
(Chapter 3) 
Functional Disability 
and HRQoL 
(Chapter 4) 
 
Rheumatoid factor 
and aCCP 
(Chapter 5) 
Shared epitope 
  
(Chapter 6) 
Circulating 
Cytokines 
(Chapter 7) 
 
Rheumatoid 
Nodules 
(Chapter 8) 
 
RA severity in 
Africans 
∙Reports of less 
severe disease in 
Africa 
∙Recent studies 
challenge this 
veiw 
 
∙ high disease 
activity with 
substantial 
radiological 
damage 
 
∙Moderate to severe 
baseline functional 
disability at  
∙poor sf-36 scores 
particularly emotional, 
body pain & physical 
role domains 
 
∙high proportion of 
RA patient were 
positive for aCCP  
and RF 
∙No correlation 
between baseline 
features and 
autoantibodies 
∙high frequency 
of SE allele (92%)  
∙SE associated 
with higher 
disease activity  
 
∙Globally increased 
cytokines, 
chemokines and 
growth factors 
∙23% of patients 
had nodules 
∙associated with 
more severe RA  
Response to 
traditional 
DMARDs  
∙in developed 
countries, about 
a third  % of 
patients achieve 
a low disease 
activity  
 
∙28% acheived 
low disease 
activity at 12 
months  
∙69% still had 
substantial functional 
disability  
∙66% had suboptimal 
mental health 
  ∙some cytokines 
were biomarkers 
of high disease 
activity, and may 
predict response 
to therapy 
 
Being poor 
matters 
 
∙Poverty worsens 
the burden of RA 
∙the group overall 
had a low level of 
education 
∙those with fewer 
years of 
schooling fared 
worse 
 
∙unemployment and 
low level of schooling 
were associated with 
worse outcomes in 
disability and mental 
health 
    
Biomarkers of RA 
 
∙elevated levels 
of circulating pro-
inflammatory 
cytokines 
∙the shared 
epitope (SE)  
confers 
susceptibility to 
RA in aCCP +ve 
patients 
  ∙strong correlations 
between auto-
antibodies and 
cytokines 
∙aCCP antibodies 
strongly associated 
SE 
∙SE associated 
with aCCP 
antibodies and 
with circulating 
cytokines and 
disease severity 
∙Circulating 
cytokines in RA 
reflect a 
multifaceted 
increase in 
immune reactivity 
 
∙Patients with 
nodules have an 
exaggerated Th1 
and macrophage 
cytokine profile, 
with significantly 
higher VEGF levels 
∙neither SE nor 
aCCP associated 
with nodules 
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Chapter 2: Patients and Methods   
  
2.1 Patients 
 
The Gauteng Region Early Arthritis (GREAT) registry is an ongoing multi-dimensional project 
at two tertiary hospitals in Gauteng, South Africa, Chris Hani Baragwanath Hospital, Soweto 
and Steve Biko Academic Hospital, Pretoria. These state-funded hospitals service a 
predominantly black African indigent urban and peri-urban population. Patients fulfilled the 
following inclusion criteria: 
1. met the 1987 revised ACR classification criteria for RA24  
2.  ≥18 years of age 
3. ≤ 2 years duration of symptoms 
4. naive to DMARD therapy at baseline 
5. stable dose of oral corticosteroids ≤  10 mg (if on any) for at least two weeks  
prior to  enrollment 
2.1.1  Recruitment of patients 
 
All patients included in the GREAT registry were referrals from primary care practitioners, 
either primary care clinics or general practitioners. Patients were screened on arrival at the 
Arthritis Clinic, and were fast-tracked with an appointment for full assessment as soon as 
possible if they appeared to meet the study inclusion criteria. 
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2.1.2  Medical therapy 
 
Standard of care was provided with DMARDs and patients were assessed at routine follow-up 
visits at 2 to 4-monthly intervals. Oral MTX, CQ or SSZ were prescribed as either 
monotherapy or combination therapy, with or without low dose oral prednisone (≤ 
7.5mg/day). Therapy was adjusted by the attending physician, based on the clinical response 
and adverse effects. No patients received anti-TNF or other biologic therapy. All patients met 
with the rheumatology nurse educator for information about the disease and therapy at first 
visit. Poor adherence to therapy was defined as failing to take DMARD therapy as prescribed 
for 1 month or longer during the 12 months period.  
2.2 Study design and assessments 
 
Al l patients gave written informed consent to participate in the study. Data for the study was 
collected at baseline, 6 months and 12 months, independent of routine clinic visits, as per 
Table 2.1. Demographic and clinical details were recorded according to a standardized case 
report form. Demographic details captured at inception included age, symptom duration, 
current employment status, highest level of education and a smoking history.  
2.2.1 Clinical Assessments  
 
At each study visit the 28-joint swollen (SJC) and tender (TJC) counts, and physician global 
assessment (a Visual Analogue Scale (VAS) of 0 to 100mm). Patients completed  a pain and  
patient global assessment score (a VAS of 0 to 100mm), the HAQ 77, and the SF-36 
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questionnaire with the help of the study coordinator if needed (Figure 2.1). The presence of 
subcutaneous nodules was documented.  
 
Table 2.1: Assessments performed at GREAT study visits 
 
HAQ:  Health assesment Questionairre, SF-36: medical short Form 36 questionairre 
 
 
 
  Baseline 6 month 
visit 
12 month 
visit 
Clinical Assessments  28-Joint Swollen and Tender Count     
Patient Global  Assessment    
Pain score    
Physician Global Assessment    
HAQ, SF-36 Questionnaire    
Laboratory 
Investigations 
ESR, CRP,  haemoglobin and 
platelet count 
   
Radiographic 
assessment 
Hand and Feet Radiographs    
Chest  Radiograph    
Serological tests  Circulating Cytokines    
Autoantibodies    
Genetic Analysis    
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Table 2.2: Disease activity formulas and definitions of disease states 
 Formula Remission 
Low 
Disease 
Activity 
Moderate 
Disease 
Activity 
High 
Disease 
Activity 
SDAI  
TJC + SJC +PGA(cm) + MDGA(cm) + 
CRP(mg/dl) ≤3.3  ≤11  >11 ≤26  >26  
DAS 28-ESR 
0.56√(TJC) + 0.28√(SJC) + 0.7ln(ESR) + 
0.014(PGA (mm)) 
 <3.2 ≥3.2 <5.1 ≥5.1 
DAS 28-CRP 
0.56√(TJC) + 0.28√(SJC)+ 
0.17ln(CRPµg/l)+1) + 0.014(PGA(mm)) 
 
SDAI: Simplified Disease Activity Index; DAS-28: 28 Joint Disease Activity Count; TJC: Tender Joint Count; SJC: 
Swollen Joint Count; PGA: patient global assessment; MDGA: physician global assessment ln: natural logarithm  
 
 
Figure 2.1: An RA patient with a symptom duration of 24 months completing a self-administered 
questionnaire at the baseline visit. Notice the difficulty with which this patient holds a pen, the “Z” thumb 
and the ulnar deviation and subluxation at the metocarpophalangeal joints of her left hand- deformities 
associated with established disease.  
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2.2.2 Disease activity  
 
Disease activity was assessed with a composite disease activity score. For chapters 3, 4 and 8, 
the SDAI was calculated, and in the case of chapter 5, the 28 joint disease activity score 
(DAS28-ESR) was used. Papers 6 and 7 used the DAS-28- CRP. Both the SDAI and theDAS-28 
(whether utilizing CRP or ESR to calculate) are validated disease activity indices, and have 
excellent correlation68. The decision to use the SDAI was based on its simplicity, hence it is 
increasingly used in clinical practice, including by the South African Rheumatism and Arthritis 
Association. Formulas for the disease activity scores and definitions of disease activity states 
are shown in Table 2.2. 
2.2.3 Functional Disability and HRQoL 
 
 “Minimal” functional disability was defined as a HAQ-DI of ≤0.5, and “substantial” functional 
disability, a HAQ-DI >0.5.  For mental health outcomes, an arbitrary cutoff point of 66.6 on 
the SF-36 mcs was used, and “good” mental health was defined as a score ≥ 66.6, versus 
“suboptimal” mental health (score <66.6). To assess change in scores from baseline, the 
minimum clinically important difference (MCID) was calculated. This is the smallest 
improvement in a score that patients perceive as beneficial, and may not be the same as a 
statistically significant difference. Based on previously published work in Western 
populations, the MCID of -0.25 and 5 for the HAQ-DI and SF-36 scores respectively were 
used168,169.  
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2.2.4 Radiographic assessment  
 
Plain radiographs of the hands and feet and chest radiography (CXR) were performed at 
baseline. Radiographs were scored by two rheumatologists (B Hodkinson and M Ally) using 
the modified Larsen method. The maximum obtainable score was 200 170. Patients were 
classified as having “erosive” disease if one or more marginal erosion was observed.  
2.2.5 Local laboratory investigations 
 
At each study visit an erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 
haemoglobin (Hb) level and platelet count were done and analysed by the National Health 
Laboratory Service at Chris Hani Baragwanath Hospital or Steve Biko Academic Hospital. 
Anaemia was defined as Hb < 12g/dl in females and < 13g/dl in males 171.  
2.2.6 Serological tests  
 
Venous blood (30ml) was collected in endotoxin-free, silicone-coated glass tubes containing a 
gel separator. The blood samples were allowed to stand at room temperature to coagulate 
(<1 hour) followed by centrifugation (3000 rpm for 10 minutes ie 1190g) after which the 
serum was removed, aliquoted, and stored at minus 20◦C until performance of the various 
assays described below. 
2.2.6.1   Auto-antibodies 
 
Rheumatoid factor was assayed by nephelometry (Siemens Healthcare Diagnostics,BN 
Prospec Nephelometer, Newark, USA) and aCCP antibodies were measured by a second 
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generation immunofluorometric procedure using the Immunocap 250 system (Phadia AB, 
Uppsala, Sweden). Values of 15 IU/ml and 10 U/ml respectively were considered positive.  
2.2.6.2   Serum cytokines, chemokines and growth factors 
 
The Bio-Plex® suspension array system (Bio-Rad Laboratories Inc, Hercules, CA, USA) which 
utilizes Luminex® xMAP  multiplex technology was used to detect and quantify multiple 
different analytes in a single sample. The following analytes were measured simultaneously: 
IL-1 , IL-1Ra, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-17A, IFN- , TNF, G-CSF, GM-CSF, CCL2, 
CCL4, and VEGF. The system uses an array of beads in liquid suspension, each containing 
different ratios of two spectrally distinct fluorophores, thereby assigning a unique spectral 
identity. The beads were then conjugated with a monoclonal antibody specific for a target 
protein. These antibody-coupled, colour-coded beads were then incubated with the serum 
sample (¼ dilutions), washed, followed by addition of a biotinylated detection antibody, 
washed again, and finally incubated with streptavidin-phycoerythrin. A wide range of 
standards (0.38 – 91756.00 pg/ml) were used to enable quantitation of the individual 
cytokines using a Bio-Plex array reader with a dual laser detector and real time digital signal 
processing. Because of the small number of controls, the upper limits of normal for these 
analytes were calculated as the mean +1SD for 10 healthy control subjects.  
2.2.6.3  Typing of HLA-DRB1 alleles 
 
 Venous blood (5ml) was collected in EDTA acid sample tubes and stored at minus 20◦C.   
Once thawed, genomic DNA was extracted using the Maxwell 16 Blood DNA Purification Kit 
(Promega, Madison, WI, USA). HLA-DRB1 alleles were determined by using a DNA-based 
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high-resolution typing method, the LABType HD Class II DRB1 Typing Test (One Lambda Inc, 
Canoga Park, CA, USA), with reverse sequence-specific oligonucleotide probes and Luminex 
technology. The target DNA (HLA-DRB1 gene) was amplified by PCR using group-specific 
primers biotinylated for detection with streptavidin R-phycoerythrin conjugate. The PCR 
product was then denatured and hybridised to complementary DNA probes conjugated to 
fluorophores. Bound DNA was detected on the Luminex system and assigned the 
represented HLA-DRB1 alleles according to the RAA amino acid sequence at positions 72-74 
as SE (S) and non-SE (X), and the S group was further subdivided according to amino acid 
groups at positions 70 and 71 as described by du Montcel et al92.  
Laboratory analysis of auto-antibodies, cytokines and genotyping was done by Dr P Meyer at 
the National Health Laboratory Service in Pretoria. 
2.3 Details of each sub-study 
 
This thesis is based on the first 171 patients enrolled in the GREAT registry between mid-
2005 and 2009. Figure 2.2 shows the patient flow for the longitudinal study and summarizes 
the subgroups of patients included in each of the papers in this thesis.  The patients included 
in the subgroup for Paper 3 were only black African patients.  The selection of patients for 
the remaining subgroups was based on patients with complete data sets at the time of 
preparing each paper. 
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Chapter 3 and 4 (Longitudinal study) 
These papers are based on a prospective observational study of 171 patients over 12 months. 
Two deaths occurred and 35 patients that were lost to follow-up, and hence data was 
available for only 134 patients at the 12-month visit. 
Chapter 5 (Cross-sectional study) 
Most studies of aCCP antibodies have been carried out on patients of European ancestry, and 
our interest was in exploring auto-antibodies in black African patients, hence only black 
patients (n=120) were included in this cross-sectional analysis. The control group consisted of 
30 healthy subjects (adults with no clinical disease), 35 systemic lupus erythematosus (SLE) 
patients and 28 systemic sclerosis (SSc) patients. These black African control patients were 
attending the Connective Tissue Disease Clinic at Chris Hani Baragwanath Hospital.  
Chapter 6 (Cross-sectional study) 
In this cross-sectional study 143 patients with complete data sets were assessed.  
Chapter 7 (Cross-sectional study) 
140 patients were included in this cross-sectional study. A control group of 10 healthy 
subjects was used to generate normal reference ranges for the cytokine levels. 
Chapter 8 (Cross-sectional study) 
This cross-sectional study was based on 149 patients with a complete set of clinical, 
radiographic, cytokine levels and genetic analysis.  
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2.4 Statistical analysis 
 
Descriptive and inferential statistical methods were performed with the assistance of an 
expert biostatistician, Eustasius Musenge from the University of the Witwatersrand 
Epidemiology Data Centre. All statistical analysis was performed using Stata 10 software 
(StataCorp, USA) or Statistica 10 (Statsoft, USA). A p value <0.05 was considered significant. 
For continuous variables, the Students t test, and where appropriate, the Wilcoxon rank sum 
test was applied. Spearman's correlation coefficient test was used to assess correlations. In 
the case of categorical variables, Pearson’s Chi-Square test, or where indicated, the 2-tailed 
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Fishers’ Exact test was used. The sensitivity, specificity and predictive powers, as well as 
Cohen’s kappa coefficient for agreement were calculated for RF and aCCP tests. Receiver 
operating characteristic (ROC) curve analysis was performed to assess the predictive powers 
of the 6 and 12 month SDAI. 
 Multivariate analyses were performed using backward stepwise logistic regression, and any 
demographic and baseline variables with a p-value ≤ 0.15 in the univariate analysis were 
included in the models.  
2.5 Strategies to maintain the cohort 
 
Patients who failed to attend their scheduled study visit were contacted by telephone in 
order to reschedule their appointments. These visits were deemed acceptable if within a 
month of the original date.  
2.6  Ethics approval 
 
The study was approved by the University of the Witwatersrand Committee for Research on 
Human Subjects (No R14/49), and the FacultY of Health Sciences Research Ethics Committees 
of the University of Pretoria (No 145/2005) (see Appendix E).  
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Chapter 3:  
 
Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans 
with early rheumatoid arthritis 
 
Summary: This publication describes disease activity at baseline and following 12 months of 
treatment, and explores predictors of response by comparing clinical characteristics of 
patients who achieve low disease activity at 12 months to those who have moderate or high 
disease activity.  
 
Statement of originality of document: please see Appendix C  
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Chapter 4:  
 
Functional Disability and Health-Related Quality Of Life in South Africans with Early 
Rheumatoid Arthritis 
 
Summary: This publication presents functional disability and quality of life in RA patients, 
evaluating improvements over 12 months of therapy and searching for demographic and 
clinical factors predicting physical disability and suboptimal mental health 
 
Statement of originality of document: please see Appendix C   
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Chapter 5:  
 
The diagnostic utility of the aCCP antibody test is no better than rheumatoid factor in South 
Africans with early rheumatoid arthritis 
 
Summary: This publication investigates anti-cyclic citrullinated peptide antibodies and 
compares their clinical utility to that of Rheumatoid Factor in this cohort. The prevalence of 
these autoantibodies is compared to that of healthy controls and patients with connective 
tissue diseases.  
Statement of originality of document: please see Appendix C   
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Chapter 6:  
 
HLA-DRB1 shared epitope genotyping using the revised classification and its association 
with circulating autoantibodies, acute phase reactants,cytokines and clinical indices of 
disease activity in a cohort of South African rheumatoid arthritis patients 
 
 
Summary: This publication explores genetic predisposition to RA in this cohort. The HLA-
DRB1 shared epitope alleles and their relationship with disease activity, circulating cytokines 
and autoantibodies are reported. 
Statement of originality of document: please see Appendix C  
 
 
 
 
 
Corrigendum note:  
Table 1 page 2 of this chapter:  
C-reactive protein concentration units are incorrect: they should be mg/l not µg/l  
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Chapter 7:  
 
Circulating Cytokine Profiles and Their Relationships with Autoantibodies, Acute Phase 
Reactants, and Disease Activity in Patients with Rheumatoid Arthritis 
 
Summary: This manuscript investigates circulating cytokines, their correlations and 
relationship with disease activity and autoantibodies. 
 
Statement of originality of document: please see Appendix C  
 
 
 
 
 
 
Corrigendum note:  
Table 2 page 3 of this chapter:  
Heading is incorrect: should read Moderate Disease Activity (MDA) not LDA 
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Chapter 8:  
 
Circulating Cytokine profile of early Rheumatoid Arthritis patients with Rheumatoid 
Nodules 
 
 
Summary: This study, submitted for publication, investigates clinical features and serum 
cytokine levels in patients with rheumatoid nodules by comparing these patients to patients 
without nodules. 
 
Statement of originality of document: please see Appendix C
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Mrs Nomvula V: December 2007 
 
The hands of Mrs Nomvula V, at enrolllment in the study. There is evidence of active disease with 
swollen second and third metacarpophalangeal joints, proximal interphalangeal joints and wrists. 
She had very active disease, with 18 swollen and 18 tender joints and an SDAI of 52.7, a pain score 
of 100mm and a global assessment of 75mm. She had poor grip strength, and struggled with 
clothes washing, particularly wringing out of clothes, and carrying groceries, and walking and 
climbing steps was difficult because of knee pain. At inception, her HAQ-DI score was 2.6. The SF 36 
questionnaire was low in the physical domains, and very low in the mental domains with vitality, 
role-emotional and social functioning the poorest areas.  
Her blood tests revealed a normochromic anaemia, and she was RF and aCCP positive. Her hand 
and feet X-rays had erosions, and the Larsen score was 36. She was started on MTX, CQ and low 
dose prednisone. Over the next year, the MTX was increased, and she received intra-articular 
steroid injections of her knees, elbows and her wrists. After 8 months of therapy she was referred to 
the social worker, who arranged childcare grants for the grandchildren. Mrs Nomvula V has also 
applied for a state disability grant, but at the 12-month visit was still waiting to hear of the 
outcome of her application. 
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Mrs Nomvula V: December 2008 
 
Mrs Nomvula V‘s hands at the 12-month visit. No synovitis or deformity is obvious in her hands, 
but she had swollen knees and elbows. She had 4 swollen and 9 tender joints and an SDAI of 22.5 
(moderate disease activity), a pain score of 75mm, and a global assessment of 75mm. Her 
physical function had improved, but still she had substantial functional impairment with a HAQ-
DI of 1.75. She continued to struggle with walking, carrying groceries but she was once again 
able to cook, wash and dress herself because her hand function had recovered. The SF-36 
physical scores had improved somewhat, as had the mental domains of social function and 
vitality, but role-emotional remained low.  At the 12-month visit, Mrs Nomvula V told me that 
she was generally better than she had been a year ago, but cited pain as her biggest burden. She 
was able to go to church most Sundays, but she was always careful “not to overdo it” because 
she knew “the pain would punish her later”. She felt her future was uncertain, and this was her 
biggest worry with the grandchildren to care for. 
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Chapter 9: Discussion  
 
This thesis describes aspects of early RA in a cohort of patients treated at either the Steve 
Biko Memorial Hospital in Pretoria or the Chris Hani Baragwanath Hospital in Soweto, South 
Africa. Against a background of few studies of early RA from developing countries, and from 
sub-Saharan Africa in particular, data on this chronic, disabling disease and its features and 
consequences in this population are urgently needed. The prospective longitudinal 
observational study fills some of the gaps in our knowledge by describing the changes in 
disease activity, physical function and health related quality of life in patients treated with 
traditional DMARD therapy and followed up with routine clinic care over 12 months. The 
cross sectional studies add to the understanding of circulating cytokines, auto-antibodies, 
susceptibility genes and a common extra-articular feature of the disease, and the 
relationships between these variables. These aspects of the disease have not been widely 
studied in South Africa or elsewhere. 
The findings will be discussed according to 4 major themes. Table 1.5 given at the end of 
Chapter 1 presents a matrix that highlights key points from each chapter as applicable to 
each theme, and these will be elaborated in the following discussion. 
i. RA severity in Africans 
ii. Response to traditional DMARDs and routine clinic care 
iii. Being poor matters 
iv. Biomarkers of RA 
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This is followed by a discussion of systems and strategies that could improve outcomes in 
South African RA patients. 
9.1     RA severity in Africans 
 
Patients in this cohort had very active disease at presentation, characterized by high swollen 
and tender joint counts, high global assessment scores, which in combination resulted in high 
composite disease activity scores. A large proportion of patients were anaemic. In spite of a 
relatively short symptom duration with a mean of about 12 months, over half of patients had 
radiographic erosions. Not surprising, therefore, that the overall cohort had moderate to 
severe functional disability, as measured by the HAQ-DI, with global impairment of HRQoL as 
measured by the SF-36. In particular, patients scored poorly in the physical domains of role 
physical, body pain, and physical function, and in mental health domains of role emotional, 
vitality, and social functioning. 
Biochemical and genetic tests showed features of severe, active RA. A high proportion of 
patients were both aCCP and RF positive (83 and 82% respectively) which is higher than 
reported elsewhere where the aCCP test and RF have moderate sensitivity in the range of 50-
70%84,85.  
 The vast majority of patients (92%) in the GREAT cohort carried one or both SE alleles. In the 
relatively few studies assessing HLA-DR genes in RA patients in Africa, a low frequency of SE-
containing alleles compared to European populations has been described (see Table 1.3). The 
low incidence of RA, mild disease and paucity of extra-articular disease has been attributed 
to these differences. In the southern African RA population, the frequency of the SE is higher 
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than that reported elsewhere in Africa, where frequencies around 40% 155-157, and as high as 
78% 158 have been described. The present study, in keeping with these reports, reveal s a 
frequency that is similar to or higher than that described amongst European RA patients154. 
A global increase in circulating cytokines and growth factors amongst patients was 
demonstrated, with particularly strong intercorrelations of cytokines amongst patients with 
very active disease.  
Nearly a quarter of patients had subcutaneous rheumatoid nodules (RN). Early RN were 
associated with high disease activity and radiological damage, suggesting more severe RA in 
this subgroup, and this is consistent with findings elsewhere52. 
The data from the present study argues against the idea that RA in Africa is generally a mild 
disease, with minimal functional disability and few extra-articular complications. Our findings 
may be different to those of previous African studies for a number of reasons. 
Firstly, there is likely to have been a referral bias. In our health care setting, only the most 
symptomatic patients are referred to specialized RA clinic. Very early or mild disease with 
few swollen joints as described in cohorts in Europe and North America were not observed. 
Hence our patients represent those at the extreme end of the severe disease spectrum and 
results are place specific and may not apply to other parts of the country. 
Secondly, the relatively late referral of patients to specialist centres may have contributed to 
the severity characteristics of the cohort. “Early” disease in developed countries is now 
accepted as symptom duration of less than 12 weeks172. In our GREAT cohort, although we 
set out to enroll patients with early disease and used symptom duration as less than 24 
months, the mean symptom duration was 11.6 months, with only 29% of patients referred 
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within 6 months, and 11% within 12 weeks of symptom duration. Strategies to reduce the 
referral and the diagnostic delay need to be explored. Additionally, there may have been 
inaccuracies in reporting the date of symptom onset, so in fact many patients had much 
more established disease than our data shows.  
Finally, the impact of urbanization and its associated environmental triggers of RA, including 
cigarette smoking and infectious agents, may be a further explanation for the severe disease 
in this urban population. In addition, climatic factors, in particular the protective effect of 
tropical infections described in Nigeria, are not relevant to temperate South Africa173.  
At baseline, the group overall had nearly every disease-specific poor prognostic feature 
identified in RA and summarized in Table 1.1. These, together with the poor SES of many of 
our patients, hold an important clinical message:  these patients require aggressive 
treatment to avoid poor outcomes. 
 
9.2 Response to traditional DMARDs and routine clinic care 
9.2.1 Disease activity 
 
 Despite improvements in disease activity of the group overall, less than a third (28%) of 
patients had low disease activity after 12 months of therapy, and remission was achieved in 
only 10% (Figures 9.1 and 9.2). These results are not dissimilar to findings elsewhere in early 
RA patients treated for 12 months with traditional DMARDs. In the  ERAN study in the UK, 
and in a mixed US and Mexican cohort and a Swedish cohort, 29%, 32% and 34% of patients, 
respectively, achieved a low disease activity state 174-176. 
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Poor prognostic factors identified in the present study included older age, high baseline 
disease activity and functional disability, low haemoglobin level and high platelet counts, 
together with a low level of formal education. These factors are consistent with predictors of 
outcome identified elsewhere, and are somewhat “intuitive’ to physicians treating RA 
patients and may be of some use to the clinician treating early RA patients. However, the 
correlation co-efficient of the multivariate model in this study shows that these factors 
accounted for only 14% of the variability in response. Complicated prediction scores have 
been devised from large databases with weighting of variables to stratify patients into 
benign, moderate or severe disease categories49,177, but these models may be of limited use 
in clinical practice. Perhaps one of the most important clinical messages arising out of the 
present study is that disease activity at 6 months was strongly predictive of disease activity at 
12 months.  This concept that early response to therapy is the most useful predictor of 
response has been shown elsewhere. In a large set of early RA patients, disease activity at 3 
months from the start of treatment correlated strongly with disease activity at 1 year178. 
Another large study of early RA patients showed that there was a low chance of achieving 
low disease activity (or minimal functional disability) during the second or third years of 
DMARD therapy if low disease activity had not been achieved during the first year174. Similar 
findings were reported in a smaller study in the Netherlands46. Hence, a passive “wait and 
see” approach, so often applied in clinical practice, and followed in the present study, in 
patients who have not achieved a suppressed level of disease within 3 to 6 months of 
therapy is unlikely to result in low disease activity.  
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Figure 9.1: A third of patients achieved low disease activity on traditional DMARD therapy. This 
patient has no synovitis, an SDAI of 3.3 and has normal hand function after 12 months of therapy. She 
continues to work as a pre-school teacher.  
 
9.2.2 Disability and HRQoL 
 
In early RA the principal determinant of physical disability is disease activity, specifically 
synovitis and pain, with improvement in HAQ-DI scores as treatment is commenced 179. This 
is in contrast to established disease, where permanent joint damage, as measured by 
radiological scores and deformity, leads to progressive disability that is less likely to 
reverse48,180. In the present study, despite improvements in functional disability in the group 
overall, a third of patients failed to achieve a clinically significant improvement in physical 
ability. At the end of 12 months of therapy, two thirds of patients still had substantial 
physical disability.  This impacted on activities of daily living: a third of patients remained 
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unable to climb a flight of stairs, could not shop for groceries independently, and 
accomplished less than they would have liked because of their physical health. There are 
relatively few reported inception cohorts of early RA that have focused on  functional 
disability and HRQoL, and the majority of these studies use Steinbrocker’s functional grading 
as a measure of disability making direct comparisons with this study difficult. Most patients 
improve, with one large study showing the percentage of patients having no functional 
impairment increasing from 33% to 40% over 5 years, with significant disability seen in only 
9% at baseline and 16% at 5 years181. In the present study, poorer outcome was seen 
amongst females, patients with poor baseline physical function and high pain scores. Studies 
elsewhere show similar risks for disability in early RA47,182,183.  
 
Figure 9.2: Despite significant improvement in disease activity in the group overall, a 
substantial number of patients remained in a moderate or high disease activity state at the 
12-month visit.. This young patient enrollled in the GREAT study clearly has severe disease 
which has responded poorly to traditional DMARD therapy, and uncontrolled wrist synovitis 
has led to partial extensor tendon rupture of fingers 3, 4 and 5. 
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In terms of mental health scores, improvements were even poorer (only 43% achieved a 
clinically meaningful change). The majority (66%) of patients had suboptimal mental health 
despite 12 months of RA treatment, with particularly blunted participation in social activities, 
poor emotional well-being and low energy levels. A large meta-analysis has shown 
depression to be 2 to 3 times more common amongst established RA patients than the 
healthy population184. As many as 40% of established RA patients met criteria for depression 
in recent studies in Japan and the USA51,185. In early disease, however, the low scores in the 
mental health scales, particularly in vitality, social functioning, and role emotional observed 
at baseline returned to normal after 12 months of either MTX or anti-TNF therapy186. 
In the present study, patients most at risk of suboptimal mental health were those who were 
unemployed, had a low level of formal education, high baseline pain and functional disability 
at baseline. Other studies have shown similar complex relationships between depression and 
pain, physical disability and SES factors 51,187,188. Katz et al refined the broad concept of 
functional impairment, and show that the loss of valued activities were the most likely to 
result in depressive symptoms. These might include simple daily tasks like cooking, visiting 
with family or neighbours, shopping or gardening189. The nature of the relationships between 
poor mental health and active disabling disease are difficult to determine, because pain and 
physical impairment can lead to depression, but equally depression is likely to hinder physical 
activity, adherence to therapy and increase pain perception. Disentangling such processes is 
difficult, and it may be that the explanations co-exist. In a recent study, patients with 
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depression were less likely to achieve remission, and reciprocally, patients who achieved 
remission were less likely to remain depressed190. 
9.3 Being poor matters 
 
Most patients in the present study were of a low SES background, with high unemployment 
rates and low levels of formal education (Figure 9.3 and 9.4). These factors no doubt 
contributed to the fairly low response rate to therapy in the group overall, and were shown 
to be predictors of poor outcome.  Patients who achieved low disease activity at 12 months 
were significantly younger and had completed more schooling than patients who remained in 
a moderate or high disease activity state. That older age was a poor prognostic factor may be 
a reflection of the pre-1994 apartheid system in which most black Africans were deprived of 
quality education. Similarly, with respect to both functional disability and mental health at 12 
months, low levels of formal education, and unemployment were poor prognostic factors. 
These links between poor SES and poor outcomes have been shown elsewhere. Margaretten 
et al refer to a “vulnerable population” of RA patients where background poverty and high 
functional disability give rise to a high risk for mental ill-health66. 
 In the absence of a validated index in South Africa, level of education and unemployment 
were used as markers of SES in the present study. Perhaps a more complex tool to better 
define the SES of a patient would show that poverty influences outcome even more strongly 
than we have demonstrated. Such a tool needs validation in the South African population, 
and needs to be updated regularly. For example, Norris et al showed that television 
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ownership in 1990 was a useful marker of good SES in Soweto, South Africa, but clearly in 
2012 most households, even indigent ones, have a television.  
Reasons for the impact of SES on clinical status are complex, and may include delays in 
initiating DMARDs with late presentation to health care services because of low awareness of 
symptoms and treatments available for arthritis. Another explanation might be limited access 
to health care. Lack of or underutilization of available resources, in particular allied health 
care, by less educated patients, may further contribute to poorer outcomes60. Lifestyle 
factors associated with poverty, including poor diet and exercise, stress exposure and weaker 
social support may worsen outcomes58,191. Indigent patients living in areas with poor 
infrastructure, including inadequate public transport necessitating walking long distances, 
carrying of water and use of outside toilets experience their physical disabilities in a much 
more profound way than wealthier patients who own a car, have domestic help and indoor 
bathrooms with hot water geysers. 
In addition, patients with poor SES are less likely to participate in leisure activities, and tend 
to “close down” their social networks when a chronic disease befalls them 192. It seems that 
patients with better education take a more active role in problem solving 193. Successful 
behavioural coping strategies might include analyzing problems from various perspectives, 
seeking different solutions and viewing problems as challenges – and this may mediate illness 
perception and the overall impact of a chronic illness such as RA 194. 
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Figure 9.3: The Soweto home of one of the study patients showing sparse socio-economic circumstances where 
basic services and facilities are largely unavailable to many RA patients. Electricity, indoor toilets and hot water 
geysers are basic services that could mitigate the symptoms of RA.  
 
Figure 9.4: This study, like studies elsewhere, showed that RA patients with poor socio-economic backgrounds 
such as this informal settlement in a district of Soweto are at risk for poor outcomes. Poor infrastructure, 
including inadequate public transport necessitating walking long distances, carrying of water and use of outside 
toilets means that RA patients experience their physical disabilities in a much more profound way than more 
affluent patients. 
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9.4 Biomarkers of RA 
 
Until recently, RF has been the principal serological marker for RA, with the recent discovery 
of aCCP which have excellent diagnostic and prognostic properties, and may be particularly 
useful in early RA. In the present study of black South Africans, the overall diagnostic 
performance of aCCP antibodies and RF was similar, with good sensitivity of both the aCCP 
test and RF (78% and 79% respectively), comparable to that reported in other populations85. 
The combination of both RF and aCCP positivity had the highest specificity, indicating that, 
ideally, both tests be done for diagnostic certainty when assessing a patient with 
inflammatory polyarthritis. However, this study supports a resource-saving strategy stepwise 
approach: testing for RF first, and performing an aCCP test only where the RF test is negative 
and there is a strong clinical suspicion of inflammatory arthritis. In this cross-sectional study, 
aCCP was not associated with any clinical or radiographic severity features, however  long-
term follow up will allow investigation of the prognostic utility of aCCP test in this population. 
The sub-study of genetic susceptibility to RA in this population revealed, as mentioned 
above, a very high occurrence of HLA-DRB1 SE alleles in RA patients. This prevalence is in 
keeping with other studies performed in South Africa, and is much higher than described 
amongst patients elsewhere in Africa. In terms of the new classification of SE risk alleles, our 
RA patients had an over-expression of the “high risk” alleles S2 and S3P, whilst the S1 allele is 
undertransmitted, a pattern similar to that seen amongst RA patients in the San population 
of southern Africa93. It has been previously shown that the genetic predisposition to RA 
conferred by the SE occurs exclusively in aCCP positive patients96,195, and the interaction 
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between citrullinated proteins and SE alleles may in fact initiate the immune response in 
RA98.  In keeping with these concepts linking genetic predisposition, auto-antibodies and 
activation of the immune system, the present study revealed an association between the SE, 
in particular the S2 and S3P alleles, with aCCP antibodies and with a Th1, Th2 and 
macrophage cytokine response together with increased IL1-Ra levels. 
 Globally increased levels of circulating cytokines, chemokines and growth factors in early RA 
patients were observed , in keeping with other studies102,196, and underscoring the central 
role of Th1 lymphocytes, macrophages and fibroblasts in the immunopathogenesis of RA. 
However, there were only weak to moderate correlations between auto-antibody and 
circulating cytokine levels, and no relationship between disease activity and circulating 
cytokines. The approach of stratifying patients according to baseline disease activity may be 
useful in the search for predictive biomarkers, because patients with highly active disease at 
baseline may have different pathogenetic events to those who start with low disease 
activity178. Of interest then, is analysis of cytokines in the subgroup of patients with high 
disease activity in the present study. In this subgroup, cytokines were highly intercorrelated 
and VEGF, a marker of angiogenesis, correlated well with other circulting cytokines, with 
radiological damage and with autoantibodies. VEGF has emerged as a major marker of 
disease activity and radiographic progression in both established and early RA197-199. These 
findings may suggest that endothelial dysfunction and angiogenesis play an important role in 
the immunopathogenesis of RA198,200, perhaps in severe disease subtypes in particular, and 
may provide another molecular target for therapy of RA. Although offering important 
information about the possible pathogenesis of RA, this study has demonstrated that neither 
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the SE nor circulating cytokines offer prognostic information over and above the traditional 
biomodel.  Further work is needed to assess the utility of baseline circulating cytokines as 
predictors of medium and long-term outcomes.  The relationship between these baseline 
biomarkers, perhaps VEGF in particular, and disease activity, radiological damage and new 
extra-articular complications of disease in this cohort needs to be extended to 2, 5 and 10 
year visits. This work is already underway.  
Rheumatoid nodules have been described in under 10% of patients with early RA, and here 
they confer a poor prognosis, predicting the development of other extra-articular 
complications and radiological damage 52,106. In the present study, 23% of patients had RN. 
Given that patients included in the study had early disease, and since RN have been 
described as rare in patients of African origin in a study of West African RA patients110, this 
high prevalence was unexpected. These patients had higher disease activity and radiographic 
damage scores than patients without RN, but there were no significant differences in terms 
of smoking history, frequency of aCCP antibodies, RF or SE alleles. 
Histopathologically, RN are immune granulomas consisting a central area of necrosis, 
surrounded by a “palisade” of macrophages and fibroblasts, and a peripheral vascular area 
containing T lymphocytes and macrophages 125.  A recent immunohistochemical study 
concluded that the RN is a Th1 granuloma based on the presence of Th1-derived cytokine 
transcripts in RNs128.  
In the subgroup study of rheumatoid nodules (RN), our results suggest the Th1-mediated 
response is exaggerated in patients with RN. Circulating cytokines of Th1 and macrophage 
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origin were significantly higher in these patients, independent of disease activity. 
Furthermore, levels of pro-angiogenic factors VEGF and IL-8 were significantly higher in RN 
patients, suggesting angiogenesis is an important feature of the RN, and may support earlier 
reports of vasculitis in the immunopathogenesis of RN 125,201. These findings may offer clues 
to the immunopathogenesis of RN and possibly other extra-articular complications of RA. 
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Chapter 10: Conclusions 
 
10.1 Limitations of the study 
 
This study has a number of limitations that require comment. Firstly, the sample size was 
relatively small. Furthermore, in the longitudinal study, there was a significant amount of 
incomplete data. Over the 12 months of the study, 20% of patients were lost to follow-up. 
These patients represent an important group because they had more severe disease at 
baseline. As mentioned above, the study cohort most likely reflects a selection bias of 
patients referred to a tertiary hospital; hence results cannot be generalized to RA patients 
elsewhere in sub-Saharan Africa. 
The follow-up period of 12 months was relatively short, and only baseline radiographic scores 
were assessed. The majority of patients in this cohort have already completed their 5-year 
visit, and data from this is under analysis. There is much information to be gained on the 
medium and long term outcomes of these patients and their relationship to baseline 
parameters. 
We relied on the SF-36 mental component score to assess depression and anxiety, and would 
have obtained better information from a specifically validated depression score. 
 
The assessment and adjustment of therapy at the routine clinic visits was performed by 
clinicians with variable expertise. We did not assess intra- and inter-observer variability in 
joint counts or global assessment scores, and clinicians were not blinded to the therapy of 
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their patients. Although this may have contributed to the low response rates, a fairly 
accurate reflection of “real life” care in most state-sector hospitals in South Africa has been 
obtained, and this is one of the strengths of this study. 
Hand and feet radiographs were scored at the baseline visit by two rheumatologists who 
assessed the x-ray simultaneously and reached a consensus score. Furthermore, the x-rays 
were performed at 2 different centres and no standard radiology protocol was followed. This 
is not ideal, and may be satisfactory for this cross-sectional study, but may cause inaccuracies 
in further longitudinal studies.   
10.2 Systems and strategies for the future 
 
I have chosen the phrase “many hands that don’t work” as a subtitle for this thesis. This is a 
reference to the RA patients who have ongoing disease activity and substantial functional 
disability despite therapy; and also alludes to the high unemployment rate amongst indigent 
South Africans. In addition, there are many hands at work in caring for rheumatoid arthritis 
patients, but this study has revealed that despite significant improvements, they are 
somewhat ineffective in relieving the patients' symptoms and the ongoing effect of those 
symptoms in their lives, and in the lives of their dependents. The web of interconnecting 
relationships that manage the care of patients is manifold and, in South Africa, beset with 
challenges. To delve too deeply into the shortcomings of the current clinical care of patients 
would be a departure from the objectives and the important findings of this thesis. In the 
interests of progress, and to inspire further research, what follows is a practical exposition of 
possibilities. 
63 
 
10.2.1  Control of disease activity 
 
The diagnostic delay is an area for improvement, because the evidence is that a delay in 
starting treatment cannot be made up in the long term20. Investigation of where the delay 
lies- in late patient presentation to health care system, or in sluggish referral from primary 
health  to tertiary centres, or a combination- will direct intervention. There is a need to 
increase public awareness of the symptoms of arthritis, and the benefits of therapies now 
available, particularly if started early, so that patients with joint symptoms visit their clinics or 
family doctor timeously. This may involve media campaigns and public awareness days- an 
extension of work started under the international “Bone and Joint Decade” initiative202. 
Primary health care workers- general practitioners, clinic sisters and doctors- need training in 
order to diagnose early inflammatory arthritis. This requires concerted efforts in continuing 
medical education programmes, with discussion of the findings of this study with respect to 
autoantibody testing, and with sharing of the new ACR diagnostic criteria to assist in early 
diagnosis26. Referral pathways can be set up at such meetings so that health care workers 
have links to each other to facilitate queries and feedback. Early arthritis clinics at tertiary 
hospitals which rapidly screen walk-in referrals with a quick joint examination, and thereafter 
“stream” patients for an urgent versus a semi-urgent assessment visit have been developed 
in Leiden, Netherlands and have been useful to referring physicians, patients and 
rheumatologists.  
The complex relationships between disease activity, pain, functional disability and mental 
health are demonstrated by this study.  Interventions to improve both physical and mental 
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health in RA may be most successful if each of these areas is addressed. Poor control of 
disease activity itself, present in over two thirds of patients, speaks to the need for new 
strategies and new drugs. Both physical disability  and mental health scores, including 
emotional well-being, improve with effective management of RA using either DMARDs or 
biologic drug therapy186. Recently it has been shown that traditional DMARDs can be used 
more effectively with minimal added expense if a “tight” control strategy is employed. Such a 
strategy involves formal assessment of disease activity at regular visits (more frequent than 
performed in the present cohort), and “treating to target” with modification of therapy 
according to a treatment algorithm if low disease activity (or ideally, remission) is not 
achieved. The TICORA study (in Glasgow, UK) showed patients managed with a tight control 
strategy were much more likely to achieve remission than those offered routine care  (65% vs 
16%, p<0.0001)203. In addition, patients had better outcomes in terms of physical function, 
health-related quality of life and radiological progression.  Similar excellent results have been 
shown elsewhere: the BeST study in the Netherlands, and FIN-RACo trial in Finland, and in 
the Netherlands204-206. Such a strategy has not yet been explored in southern Africa.  
Patients who do not show an adequate response to therapy within 3 to 6 months require 
new strategies. This might include combination DMARDs, addition of another DMARD such as 
leflunomide as monotherapy or in combination with MTX. There is also clearly a need for 
biologic therapy in patients who have ongoing active disease, although access to these drugs 
remains a challenge in our setting. Clinicians need to lobby on behalf of their patients, both 
to the pharmaceutical industry to reduce the cost of these drugs to within reach of resource-
constrained settings such as ours, and to the state sector to provide funding for these drugs, 
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taking into account the long term cost-effectiveness of disease control which has been shown 
elsewhere207.  
10.2.2   Mobility 
 
There is clearly a need for more aggressive rehabilitation by allied health professionals for RA 
patients. Physiotherapy programmes need to be accessible (perhaps run at local clinic level), 
and practical, exploring new ways to keep patients on an exercise programme. A recent study 
in the Netherlands showed that “motivational interviewing” is a useful strategy to enhance 
motivation and thus improve participation in exercise and joint strengthening programmes 
208. Such an approach could be explored in our context. Occupational therapy has a central 
role to play in the ergonomic assessment of a patient’s home and workplace, splinting and 
adaptative equipment guidance and education for patients and family members (Figure 
10.1). The Chris Hani Baragwanath  Hospital hand occupational therapist, Carin Dreijer du 
Plessis, successfully showed that intensive week-long inpatient training sessions, with home 
visits, in our RA patients, were very effective, with improvements in both functional disability 
and mental health scores209. We need larger scale initiatives to come out of this work.  
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10.2.3  Mental Health 
 
Closer links with psycho-social services with screening for and treatment of depression at 
baseline and at follow-up visits are called for. Recent work showed a simple 2-question 
screening test for depression to be useful and practical210. These two questions are “Have 
you felt down, depressed or hopeless over the last 2 weeks?” or “Have you little interest or 
pleasure in doing things over the last 2 weeks?” . We need to explore this test or adapt it for 
our patients.  Strategies to treat depression might include individual and group therapy 
sessions, as well as antidepressants.  Self-management techniques including cognitive 
Figure 10.1: A Futura wrist splint worn by a GREAT study participant. Such a splint reduces pain and improves task 
performance. Occupational therapists offer RA patients instruction on joint protection and energy conservation, 
education and counselling, assistive devices and splints, resulting in improved functional performance and social 
participation. Rehabilitation teams may have been underutilised in this study, and outcomes may be improved by 
early referral and intensive inpatient sessions. 
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behavioral therapy and relaxation techniques have been shown to improve pain, self-care 
and participation in social events211,212. A recent study by psychiatrists in Connecticut, US 
asked RA patients to report their daily pain, mood and activities for 75 consecutive days213. 
This study confirmed the relationship between depression or anxiety and heightened joint 
pain. There were coping strategies, including relaxation, distraction and support-seeking, 
observed amongst patients with low pain scores and positive moods that could be of use to 
other RA patients. There are likely to be lessons to learn from RA patients in South Africa who 
cope with pain that we have not considered formally exploring. Antidepressants in depressed 
patients with musculoskeletal disease have been shown to improve not only mental health 
status, but physical disability and pain scores214. The effectiveness of these and other 
strategies in South Africa are areas for further research. 
10.3.4 Maintaining relationships 
 
The solutions to poor adherence to chronic medication are complex, because the ability of a 
patient to follow her treatment plan is compromised by any one or more of a number of 
“barriers” 215. These might include economic and social factors; problems with access to the 
health care system; patient-related factors, and the therapy itself. Amongst our patients, 
reasons for not returning for treatment may be related to poor SES, where the cost of 
transport to and from hospital, and the consequences of a day of unpaid leave for patients 
with jobs, was a deterrent. A service to supply monthly medication to the nearest clinic or to 
the patient’s home would greatly assist patients, and very likely improve treatment 
adherence.  Some patients, particularly those doing badly on treatment, may have sought 
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alternative treatment at other hospitals or with traditional healers. Others did not “buy into” 
the importance of early aggressive DMARD therapy. Our message failed to take root. 
Intuitively, it seems that communication with patients about their disease and treatment 
offered could be helpful. All patients enrolled in this cohort had a brief education session 
about the disease and the medication prescribed. In addition, all RA patients attending the 
Arthritis Clinic attend a midday group multidisciplinary meeting where the rheumatology 
nurse educator, an occupational therapist, physiotherapist, social worker and podiatrist 
speak briefly about RA and then answer individual questions. This session was cited by 
patients as being very useful163. These existing sessions need to be maintained and 
developed. Perhaps abstract information about the disease and the interventions available to 
retard disease progression may be of use to well educated patients in Europe and North 
America, although interestingly research has not proven such sessions to improve 
adherence216. A new approach is called for in southern Africa, centered on our patients, with 
their unique references, belief systems and individual domestic situations. Patients need to 
be invited to participate in interactive sessions which are facilitated by a rheumatology nurse 
practitioner. Such sessions would offer non-medical explanations of the disease and 
treatment options, and give patients a good understanding of how to take the prescribed 
therapy and an idea of possible side-effects that might be experienced. The session could 
conclude with a discussion of expectations, and realistic goal setting. Education sessions are 
more effective when combined with a patient-focused educational booklet that patients can 
take home and read with their families217. Such material needs to be developed in South 
Africa and translated into local languages. In addition, family and, where applicable, 
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employer support can play a large role in improving adherence. Patients could be encouraged 
to enlist the understanding and help of family, employers and colleagues. Awareness of 
chronic illnesses, and musculoskeletal problems, amongst the community could be widened 
via television and radio programmes, and this would benefit patients. 
An untapped resource is RA patients themselves. An opportunity for a newly diagnosed RA 
patient to meet and interact with patients who have lived with the disease and its therapies 
for many years could offer inspiration and sharing of coping strategies. Soweto has a few 
arthritis support groups, but more patients could benefit from a wider-reaching programme 
which specifically includes newly diagnosed RA patients.  
The challenge is also to arthritis clinics, at secondary or tertiary level, to improve the service 
offered. Smoother clinic running with short waiting times, and an opportunity for relaxation 
and refreshment for patients whilst waiting for a consultation would be ideal (Figure 10.2). A 
“call-in” service for disease flares could be beneficial. Patient-centred assessments, 
incorporating the patients’ agenda and interests, could shift the physician-patient 
relationship from passive and somewhat unproductive to a more interactive and 
empowering partnership, resulting in better patient retention and adherence, and indeed 
better disease outcomes. Measuring outcomes that are important to patients, rather than 
just capturing outcomes that clinicians are interested in, is a growing field in modern 
rheumatology, and deserves attention in our context. A simple question like “Which areas 
would you most like to see improvements in the next 6 months?” from the rheumatology 
nurse, the occupational therapist or physician could yield important answers, and encourage 
patients to prioritize their difficulties218. Another enquiry that captures the loss of valued 
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activities might be “Can you do the things that you want to do? If not, list these activities” 
which could complement the HAQ-DI and allow health care workers and patients to focus on 
solutions together189. 
10.2.6 RA specialists at every level of the care team 
 
A significant advance in modern rheumatology is the recognition of the importance of the 
rheumatology nurse practitioner.  The responsibilities of such a professional include drug 
monitoring, education, counseling of patients and co-ordinating the multidisciplinary team 
caring for an RA patient. It has been shown that rheumatology nurse practitioners are of 
great benefit to patients and central to the operation of the multidisciplinary team 219,220. 
Training programmes have been developed in Europe and North America, and there is clearly 
a need to train specialist nurses in the field of rheumatology in South Africa.  
Ongoing training and support of all health care workers is needed, because patients bear the 
brunt of poor care from overstretched and “burnt-out” nurses, administrative personnel and 
doctors. Patients need to feel that they are seen and heard as individuals, and this is 
impossible to achieve if staff are not nurtured and acknowledged. Empowered health care 
can empower patients. 
“Shared care” has been very successful in Europe. In such a programme, patients are 
diagnosed with RA and started on therapy, and once they achieve  remission or low disease 
activity, are referred back to primary care doctors for treatment and monitoring, with 6 to 12 
monthly reviews by a rheumatologist at a tertiary centre. This approach is convenient and 
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less costly for patients, and makes better use of health care facilities. In SA we have failed to 
set up such partnerships, and better primary health care facilities, training and support of 
their staff and dispensaries might allow such programmes to begin. 
 
 
Figure 10.2: Queuing for care. The long waiting times in our clinic, with rows of patients waiting much 
of the day to be seen by a doctor, could be used more effectively. A more patient-centred clinic, with 
meaningful interaction and support group meetings could take place in this time. This may improve 
adherence to therapy and to follow-up visits, and would empower patients and very likely improve 
outcomes.  
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10.2.7  Better use of resources 
 
South Africa, in comparison to other sub-Saharan African countries, has plentiful resources. 
There are more effective ways to use these existing resources, applicable to both health care 
planners and to individual patients themselves. This is an area where South Africans often fall 
short, preferring to feel that they are indigent and trapped rather than looking for solutions, 
not necessarily financial ones, to improve their situation. As members of the health care 
team, we need to focus on using existing resources more effectively, endeavoring to share 
this attitude with our patients.    
“It is what we make out of what we have, not what we are given, that separates one 
person from another.” 
Nelson Mandela, 1995 221 
 
 
 
10.2.8  Public services 
 
There are other unmet needs that are highlighted by this study, falling within the realms of 
social services and government departments. These include job retention in patients who 
have jobs, and better public transport systems so that indigent patients with disabilities have 
fewer challenges not just with hospital attendance, but also to maintain their occupational 
and social lives. There is an urgent need to develop stronger partnerships not just within the 
medical team, but in the domains of transport, and the pharmaceutical industry to allow 
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patient-centred health care services. There is a social message, common to all chronic 
disorders that highlightS the fundamental importance of formal education at primary and 
secondary school level. Lack of formal education has grim consequences on many facets of 
an individual and her community. In SA, our broken education system urgently needs 
attention for the sake of tomorrow’s adults.  
In health, there is freedom. Health is the first of all liberties. 
Henri-Frederic Amiel, 1860 222 
In our young democracy, freedom will only be truly realized when we can offer good health 
care to all the peoples of South Africa. 
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10.3  The way forward 
Unmet needs and areas for future action and research are highlighted by the present study. 
In particular, new treatment approaches, including intense patient education and biologic 
therapy, might allow better outcomes to be achieved. Earlier referrals of inflammatory 
arthritis to specialist centres need to be encouraged.  
Long-term follow up of this cohort might allow the prognostic utility of the aCCP test and the 
SE in this population to be established. Further work is needed to assess the role of baseline 
circulating cytokines as predictors of medium and long-term outcomes. 
An investigation of the changes in circulating cytokine profiles of patients with RN and other 
extra-articular complications over time and with therapy, accompanied by 
immunohistochemical studies, will be of interest.  
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Appendices 
A. Health Assessment Questionnaire 
 
 
We are interested in learning how your illness affects your ability to function in daily life. Please feel free to add 
any comments at the end of this form. 
Please tick the one response, which best describes your usual abilities over the past week. 
 
 Without ANY With SOME             With MUCH  Unable 
 Difficulty  difficulty  difficulty  to do 
1.  DRESSING AND GROOMING Are you able to: 
 Dress yourself, including tying shoelaces and doing buttons?         
 Shampoo your hair?           
2. RISING Are you able to: 
 Stand up from an armless straight chair?          
 Get in and out of bed?          
3.  EATING   Are you able to: 
 Cut your meat?          
 Lift a full cup or glass to your mouth?          
 Open a new carton of milk or soap powder?          
4. WALKING    Are you able to: 
 Walk outdoors on flat ground?          
 Climb up five steps?          
          
 Please tick the one response, which best describes your usual abilities over the past week. 
 Without ANY With SOME With MUCH Unable 
 Difficulty  difficulty  difficulty  to do 
5.  HYGIENE  Are you able to: 
 Wash and dry your entire body?         
 Take a bath?           
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 Get on and off the toilet?          
6. REACH     Are you able to: 
 Reach and get down a 2kg object (e.g. bag of potatoes) 
 from just above your head?          
 Bend down to pick up clothing from the floor?          
7.  GRIP    Are you able to: 
 Open car doors?          
 Open jars, which have been previously opened?          
 Turn taps on and off?          
8. ACTIVITIES     Are you able to: 
 Run errands and shop?          
 Get in and out of a car?          
 Do chores such as vacuuming, housework or light gardening?          
 
Please tick any aids or devices that you usually use for any of these activities: 
  Raised toilet seat   Bath rail 
  Bath seat   Long handled appliances for reach 
  Jar opened (for jars previously opened)  
Other (Specify):       
Please tick any categories for which you usually need help from another person: 
  Dressing and Grooming   Eating   Rising   
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B. SF-36 Questionnaire 
 
 
INSTRUCTIONS: THIS QUESTIONNAIRE ASKS FOR YOUR VIEWS ABOUT YOUR HEALTH. THIS INFORMATION WILL HELP KEEP TRACK OF 
HOW YOU FEEL AND HOW WELL YOU ARE ABLE TO DO YOUR USUAL ACTIVITIES. PLEASE BE SURE TO ANSWER EACH QUESTION BY 
CIRCLING ONE OF THE RESPONSES PROVIDED. IF YOU ARE UNSURE ABOUT HOW TO ANSWER A QUESTION, GIVE THE BEST ANSWER 
YOU CAN. 
1. IN GENERAL, WOULD YOU SAY YOUR HEALTH IS: 
 EXCELLENT  1 VERY GOOD  2 GOOD  3 FAIR  4 POOR  5 
 
2.  COMPARED TO ONE YEAR AGO, HOW WOULD YOU RATE YOUR HEALTH IN GENERAL NOW? 
MUCH BETTER NOW THAN ONE YEAR AGO   1 
SOMEWHAT BETTER NOW THAN ONE YEAR AGO   2 
ABOUT THE SAME AS A YEAR AGO   3 
SOMEWHAT WORSE NOW THAN ONE YEAR AGO   4 
MUCH WORSE NOW THAN ONE YEAR AGO   5 
 
3. THE FOLLOWING ITEMS ARE ABOUT ACTIVITIES YOU MIGHT DO DURING A TYPICAL DAY.  DOES YOUR HEALTH NOW LIMIT YOU IN 
THESE ACTIVITIES?  IF SO, HOW MUCH? 
ACTIVITIES YES, LIMITED YES, LIMITED NO, NOT 
 A LOT A LITTLE LIMITED AT ALL 
A. VIGOROUS ACTIVITIES, SUCH AS RUNNING, LIFTING HEAVY 
OBJECTS, PARTICIPATING IN STRENUOUS SPORTS 1 2 3 
B. MODERATE ACTIVITIES, SUCH AS MOVING A TABLE, PUSHING 
A VACUUM CLEANER, BOWLING OR PLAYING GOLF 1 2 3  
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C. LIFTING OR CARRYING GROCERIES 1 2 3 
D. CLIMBING SEVERAL FLIGHTS OF STAIRS 1 2 3 
E. CLIMBING ONE FLIGHT OF STAIRS 1 2 3 
F. BENDING, KNEELING OR STOOPING 1 2 3 
G. WALKING MORE THAN A MILE 1 2 3 
H. WALKING SEVERAL BLOCKS 1 2 3 
I. WALKING ONE BLOCK 1 2 3 
J. BATHING OR DRESSING YOURSELF 1 2 3 
4. DURING THE PAST 4 WEEKS, HAVE YOU HAD ANY OF THE FOLLOWING PROBLEMS WITH YOUR WORK OR OTHER REGULAR DAILY 
ACTIVITIES AS A RESULT OF YOUR PHYSICAL HEALTH?  YES NO 
A. CUT DOWN THE AMOUNT OF TIME YOU SPENT ON WORK OR OTHER  1 2 
 ACTIVITIES 
B. ACCOMPLISHED LESS THAN YOU WOULD LIKE 1 2 
C. WERE LIMITED IN THE KIND OF WORK OR OTHER ACTIVITIES 1 2 
D. HAD DIFFICULTY PERFORMING THE WORK OR OTHER ACTIVITIES 1 2 
 (E.G., IT TOOK EXTRA EFFORT) 
5. DURING THE PAST 4 WEEKS, HAVE YOU HAD ANY OF THE FOLLOWING PROBLEMS WITH YOUR WORK OR OTHER REGULAR DAILY 
ACTIVITIES AS A RESULT OF EMOTIONAL PROBLEMS (SUCH AS FEELING DEPRESSED OR ANXIOUS)? 
  YES NO 
A. CUT DOWN THE AMOUNT OF TIME YOU SPENT ON WORK OR OTHER  1 2 
 ACTIVITIES 
B. ACCOMPLISHED LESS THAN YOU WOULD LIKE 1 2 
C. DIDN’T DO WORK OR OTHER ACTIVITIES AS CAREFULLY AS USUAL 1 2 
6. DURING THE PAST 4 WEEKS, TO WHAT EXTENT HAS YOUR PHYSICAL HEALTH OR EMOTIONAL PROBLEMS INTERFERED WITH YOUR 
NORMAL SOCIAL ACTIVITIES WITH FAMILY, FRIENDS, NEIGHBORS, OR GROUPS? 
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 NOT AT ALL  1                       SLIGHTLY  2                        MODERATELY  3 QUITE A BIT  4 EXTREMELY  5 
7. HOW MUCH BODILY PAIN HAVE YOU HAD DURING THE PAST 4 WEEKS? 
NONE  1              VERY MILD  2            MILD  3                    MODERATE  4            SEVERE  5               VERY SEVERE  6 
8. DURING THE PAST 4 WEEKS, HOW MUCH DID PAIN INTERFERE WITH YOUR NORMAL WORK (INCLUDING BOTH WORK OUTSIDE 
THE HOME AND HOUSEWORK)? 
NOT AT ALL  1 A LITTLE BIT  2 MODERATELY  3 QUITE A BIT  4 EXTREMELY  5 
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 9. THE FOLLOWING QUESTIONS ASK HOW YOU FEEL AND HOW THINGS HAVE BEEN WITH YOU DURING THE PAST 4 WEEKS.  
FOR EACH QUESTION, PLEASE GIVE THE ONE ANSWER THAT COMES CLOSEST TO THE WAY YOU HAVE BEEN FEELING.  
 HOW MUCH OF THE TIME DURING THE PAST 4 WEEKS 
  ALL OF MOST OF A GOOD BIT SOME OF A LITTLE OF NONE OF 
  THE TIME THE TIME OF THE TIME THE TIME THE TIME THE TIME 
 
A. DID YOU FEEL FULL OF PEP? 1 2 3 4 5 6 
 
B. HAVE YOU BEEN A VERY  
NERVOUS PERSON?  1 2 3 4 5 6 
 
C. HAVE YOU FELT SO DOWN IN 
THE DUMPS THAT NOTHING 
COULD CHEER YOU UP?  1 2 3 4 5 6 
 
D. HAVE YOU FELT CALM 
AND PEACEFUL? 1 2 3 4 5 6 
 
E. DID YOU HAVE A LOT 
OF ENERGY?  1 2 3 4 5 6 
 
F. HAVE YOU FELT 
DOWNHEARTED AND BLUE?  1 2 3 4 5 6 
 
G. DID YOU FEEL WORN OUT?  1 2 3 4 5 6 
 
H. HAVE YOU BEEN A HAPPY  
PERSON?  1 2 3 4 5 6 
 
I. DID YOU FEEL TIRED?  1 2 3 4 5 6 
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10. DURING THE PAST 4 WEEKS, HOW MUCH OF THE TIME HAS YOUR PHYSICAL HEALTH OR EMOTIONAL PROBLEMS INTERFERED 
WITH YOUR SOCIAL ACTIVITIES (LIKE VISITING WITH FRIENDS, RELATIVES, ETC.)?  
 
  ALL OF MOST OF SOME OF A LITTLE OF NONE OF 
  THE TIME THE TIME THE TIME THE TIME THE TIME 
  1 2 3 4 5 
 
11. HOW TRUE OR FALSE IS EACH OF THE FOLLOWING STATEMENTS FOR YOU.  
 
 DEFINITELY MOSTLY DON’T MOSTLY DEFINITELY 
 TRUE TRUE KNOW FALSE FALSE 
A. I SEEM TO GET SICK A LITTLE 
EASIER THAN OTHER PEOPLE 1 2 3 4 5 
B. I AM HEALTHY AS ANYBODY I KNOW 1 2 3 4 5 
C. I EXPECT MY HEALTH TO GET WORSE 1 2 3 4 5 
D. MY HEALTH IS EXCELLENT 1 2 3 4 5 
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